EMI Holding 10-Q 14 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 10, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	EMMAUS LIFE SCIENCES, INC.
Entity Central Index Key	0001420031
Document Type	10-Q
Trading Symbol	EMMA
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity's Reporting Status Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		36,051,394
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents ($13,071 and $13,175 attributable to the VIE)	$ 15,310	$ 17,080
Accounts receivable, net	1,760	1,351
Inventories, net	5,795	4,705
Investment in marketable securities	42,873	49,343
Marketable securities, pledged to creditor	251	238
Prepaid expenses and other current assets ($271 and $273 attributable to the VIE)	818	743
Total current assets	66,807	73,460
PROPERTY AND EQUIPMENT, NET	153	152
OTHER ASSETS
Long-term investment at cost	527	538
Intangibles, net	50	54
Right of use assets	2,838
Deposits and other assets	360	352
Total other assets	3,775	944
Total assets	70,735	74,556
CURRENT LIABILITIES
Accounts payable and accrued expenses	11,068	9,122
Deferred rent		19
Operating lease liabilities	682
Other current liabilities	5,217	5,181
Notes payable, net	7,000	6,394
Notes payable to related parties, net	470	468
Convertible notes payable, net	15,157	11,253
Convertible notes payable to related parties, net	13,896	5,089
Total current liabilities	53,490	37,526
LONG-TERM LIABILITIES
Deferred rent		268
Operating lease liabilities	2,478
Other long-term liabilities	35,637	36,222
Warrant derivative liabilities	1,447	1,399
Notes payable, net	1,922	1,021
Convertible notes payable, net	389	5,485
Convertible notes payable to related parties, net		8,529
Total long-term liabilities	41,873	52,924
Total liabilities	95,363	90,450
STOCKHOLDERS’ DEFICIT
Preferred stock — par value $0.001 per share, 20,000,000 shares authorized, none issued and outstanding
Common stock — par value $0.001 per share, 100,000,000 shares authorized, 35,947,804 shares and 35,558,305 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively	36	36
Additional paid-in capital	146,344	140,904
Accumulated other comprehensive income (loss)	(62)	(69)
Accumulated deficit	(170,864)	(156,668)
Total stockholders’ deficit	(24,546)	(15,797)
Noncontrolling interests	(82)	(97)
Total liabilities & stockholders’ deficit	$ 70,735	$ 74,556

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, authorized	20,000,000	20,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	100,000,000	100,000,000
Common stock, issued	35,947,804	35,558,305
Common stock, outstanding	35,947,804	35,558,305
Cash and cash equivalents	$ 15,310	$ 17,080
Prepaid expenses and other current assets	818	743
Variable Interest Entity [Member]
Cash and cash equivalents	13,071	13,175
Prepaid expenses and other current assets	$ 271	$ 273

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
REVENUES, NET	$ 5,307	$ 781
COST OF GOODS SOLD	200	134
GROSS PROFIT	5,107	647
OPERATING EXPENSES
Research and development	513	411
Selling	1,485	870
General and administrative	3,681	3,807
Total operating expenses	5,679	5,088
LOSS FROM OPERATIONS	(572)	(4,441)
OTHER INCOME (EXPENSE)
Loss on debt extinguishment		(3,245)
Change in fair value of warrant derivative liabilities	(48)	840
Change in fair value of embedded conversion option		466
Net gains (losses) on equity investment in marketable securities	(6,457)	5,535
Interest and other income (loss)	(111)	46
Interest expense	(6,965)	(5,298)
Total other income (expenses)	(13,581)	(1,656)
LOSS BEFORE INCOME TAXES	(14,153)	(6,097)
NET LOSS INCLUDING NONCONTROLLING INTERESTS	(14,153)	(6,097)
Net (income) loss attributable to noncontrolling interests	(14)
NET LOSS ATTRIBUTABLE TO THE COMPANY	(14,167)	(6,097)
COMPONENTS OF OTHER COMPREHENSIVE INCOME (LOSS)
Foreign currency translation adjustments	8	14
Other comprehensive income (loss)	8	14
COMPREHENSIVE INCOME (LOSS)	(14,145)	(6,083)
Amounts attributable to noncontrolling interests:
Net (income) loss attributable to noncontrolling interests	(14)
Foreign currency translation adjustments	(1)
Comprehensive (income) loss attributable to noncontrolling interest	(15)
COMPREHENSIVE INCOME (LOSS) ATTRIBUTABLE TO THE COMPANY	$ (14,160)	$ (6,083)
NET LOSS PER COMMON SHARE	$ (0.40)	$ (0.17)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING	35,684,038	34,891,450

CONSOLIDATED STATEMENT OF CHANG

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Treasure Stock, at cost [Member]	Accumulated Deficit [Member]	Total Emmaus Stockholders' Equity / Deficit [Member]	Non-controlling Interests [Member]
Balance, beginning at Dec. 31, 2017	$ 14,291	$ 35	$ 113,112	$ 41,276		$ (140,132)	$ 14,291
Balance, beginning (in shares) at Dec. 31, 2017		34,885,506
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect adjustment on adoption | ASU 2016-01 [Member]				(41,362)		41,362
Beneficial conversion feature relating to convertible and promissory notes payable	3,638		3,638				3,638
Stock issued for cash	275		275				275
Stock issued for cash (in shares)		25,000
Repurchase of common stock	(1,314)				$ (1,314)		(1,314)
Share-based compensation	710		710				710
Foreign currency translation effect	14			14			14
Net income (loss)	(6,097)					(6,097)	(6,097)
Balance, ending at Mar. 31, 2018	11,517	$ 35	117,735	(72)	$ (1,314)	(104,867)	11,517
Balance, ending (in shares) at Mar. 31, 2018		34,910,506
Balance, beginning at Dec. 31, 2017	14,291	$ 35	113,112	41,276		(140,132)	14,291
Balance, beginning (in shares) at Dec. 31, 2017		34,885,506
Balance, ending at Dec. 31, 2018	(15,894)	$ 36	140,904	(69)		(156,668)	(15,797)	$ (97)
Balance, ending (in shares) at Dec. 31, 2018		35,558,305
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect adjustment on adoption | ASU 2016-01 [Member]	41,400
Cumulative effect adjustment on adoption | ASC 842 [Member]	(29)					(29)	(29)
Beneficial conversion feature relating to convertible and promissory notes payable	2,039		2,039				2,039
Exercise of warrants	5		5				5
Exercise of warrants (in Shares)		500
Stock issued for cash	2,530		2,530				2,530
Stock issued for cash (in shares)		307,500
Conversion of notes payable to common stock	329		329				329
Conversion of notes payable to common stock (in shares)		81,332
Share-based compensation	536		536				536
Exercise of common stock options	1		1				1
Exercise of common stock options (in shares)		167
Foreign currency translation effect	8			7			7	1
Net income (loss)	(14,153)					(14,167)	(14,167)	14
Balance, ending at Mar. 31, 2019	$ (24,628)	$ 36	$ 146,344	$ (62)		$ (170,864)	$ (24,546)	$ (82)
Balance, ending (in shares) at Mar. 31, 2019		35,947,804

CONSOLIDATED STATEMENT OF CHA_2

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (unaudited) (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement Of Stockholders Equity [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized	100,000,000	100,000,000

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (14,153)	$ (6,097)
Adjustments to reconcile net loss to net cash flows from operating activities
Depreciation and amortization	17	13
Cost of scrapped inventory written off		8
Amortization of discount of convertible notes	5,641	4,192
Foreign exchange adjustments on convertible notes and notes payable	(19)	135
Net losses (gains) on equity investment in marketable securities	6,457	(5,535)
Loss on debt settlement		3,245
Share-based compensation	536	710
Change in fair value of warrant derivative liabilities	48	(840)
Change in fair value of embedded conversion option		(466)
Net changes in operating assets and liabilities
Accounts receivable	(409)	(658)
Inventories	(1,091)	(388)
Prepaid expenses and other current assets	(83)	94
Other non-current assets	(2,813)	(84)
Accounts payable and accrued expenses	2,339	(539)
Deferred revenue	500	596
Deferred rent	(287)	(41)
Other current liabilities	36	40
Other long-term liabilities	1,997	5,000
Net cash flows used in operating activities	(1,284)	(615)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(16)	(15)
Purchase of marketable securities and investment at cost		(469)
Net cash flows used in investing activities	(16)	(484)
CASH FLOWS FROM FINANCING ACTIVITIES
Repurchase of common stock and warrants		(7,500)
Proceeds from convertible notes payable issued, net of issuance cost and discount		14,395
Payments of notes payable		(3,500)
Payments of convertible notes	(3,048)	(20,000)
Proceeds from exercise of warrants	5
Proceeds from issuance of common stock	2,530	275
Proceeds from conversion of notes payable to common stock	21
Net cash flows used in financing activities	(492)	(16,330)
Effect of exchange rate changes on cash	22	(14)
Net decrease in cash, cash equivalents and restricted cash	(1,770)	(17,443)
Cash and cash equivalents, beginning of period	17,080	22,556
Cash and cash equivalents, end of period	15,310	5,113
SUPPLEMENTAL DISCLOSURES OF CASH FLOW ACTIVITIES
Interest paid	385	$ 371
Conversion of notes payable to common stock	$ 308

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 1 — BASIS OF PRESENTATION The accompanying unaudited consolidated interim financial statements of Emmaus Life Sciences, Inc. and subsidiaries (collectively, the “Company” or “Emmaus”) have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) on the basis that the Company will continue as a going concern. The consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All significant intercompany transactions have been eliminated. The Company’s unaudited consolidated interim financial statements contain adjustments, including normal recurring accruals necessary to present fairly the Company’s consolidated financial position, results of operations, and cash flows. Due to the uncertainty of the Company’s ability to meet its current operating and capital expenses, there is substantial doubt about the Company’s ability to continue as a going concern, as the continuation and expansion of its business is dependent upon obtaining further financing, market acceptance of Endari™, and achieving a profitable level of revenues. The consolidated interim financial statements do not include any adjustments that might result from the outcome of these uncertainties. The consolidated interim financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission (“SEC”) on March 21, 2019 (the “Annual Report”). Interim results for the periods presented herein are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2019. The preparation of the consolidated financial statements requires the use of management estimates. Actual results could differ materially from those estimates.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Refer to the Annual Report for a summary of significant accounting policies. There have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2019 except for leases, which are discussed below. Below are disclosures of certain interim balances, transactions, and significant assumptions used in computing fair value as of and for the three months ended March 31, 2019 and comparative amounts from the prior fiscal periods: Revenues – Effective January 1, 2018, the Company adopted Accounting Standard codification (“ASC”) Topic 606, Revenue from Contracts with Customers using the modified retrospective transition methods. The adoption of ASC 606 did not have a material impact on the measurement or on the recognition of revenue of contracts for which all revenue had not been recognized as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of accumulated deficit at the beginning of 2018. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the periods presented. Since January 2018, the Company has generated revenues through the sale of Endari as a treatment for sickle cell disease (“SCD”). The Company also generates revenues to a much lesser extent from the sale of AminoPure®, a nutritional supplement. Revenues from Endari product sales are recognized upon delivery and transfer of control of products to the Company’s distributors and specialty pharmacy customers. Distributors resell the products to other specialty pharmacy providers, health care providers, hospitals, patients and clinics. In addition to distribution agreements with distributors, the Company enters into contractual arrangements with specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities that provide for government-mandated or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. These various discounts, rebates, and charge-backs are referred to as “variable consideration.” Revenues from product sales are recorded net of variable consideration. Prior to recognizing revenues, the Company’s management forecasts and estimates variable consideration. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Provisions for returns and other variable consideration adjustments are provided for in the period in which the related revenues are recorded. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. The following are our significant categories of sales discounts and allowances: Sales Discounts: The Company provides its customers contractual prompt payment discounts and from time to time offers additional one-time discounts that are recorded as a reduction of revenues in the period the revenues are recognized. Product Returns: The Company offers its distributors a right to return product purchased directly from the Company based principally upon (i) overstocks, (ii) inactive product or non-moving product due to market conditions, and (iii) expired products. Product return allowances are estimated and recorded at the time of sale. Government Rebates: The Company is subject to discount obligations under state Medicaid programs and the Medicare prescription drug coverage gap program. The Company’s management estimates Medicaid and Medicare prescription drug coverage gap rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenues are recognized, resulting in a reduction of product revenues and the establishment of a current liability that is included as accounts payable and accrued expenses in our balance sheet. The liability for these rebates consists primarily of estimates of claims expected to be received in future periods related to the recognized revenues. Chargebacks and Discounts: Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to certain specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities at prices lower than the list prices charged to distributors. The distributors charge the Company for the difference between what they pay for the products and the Company’s contracted selling price to these specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities. These reserves are established in the same period that the related revenues are recognized, resulting in a reduction of revenues. Chargeback amounts are generally determined at the time of resale of products by the distributors. — As described below under "Recent accounting pronouncements Prior to our adoption of ASU 2016-02, when our lease agreements contained tenant improvement allowances and rent escalation clauses, we recorded a deferred rent asset or liability equal to the difference between the rent expense and the future minimum lease payments due. The lease expense related to operating leases was recognized on a straight-line basis in the statements of operations over the term of each lease. In cases where the lessor granted us leasehold improvement allowances, we capitalized the improvements as incurred and recognized it over the shorter of the lease term or the expected useful life of the improvements. Inventories — Substantially all of the raw material purchased during the three months ended March 31, 2019 and for the year ended December 31, 2018 were from one vendor. The below table presents inventory by category (in thousands): Inventories by category March 31, 2019 December 31, 2018 Raw materials and components $ 647 $ 171 Work-in-process 1,584 2,471 Finished goods 3,564 2,063 Total $ 5,795 $ 4,705 Marketable securities — The Company’s marketable securities consist of the following securities; (a) 39,250 shares of capital stock of CellSeed, Inc. (“CellSeed”) acquired in January 2009 at ¥680 JPY per share ($7.69 USD); (b) 6,643,559 shares of capital stock of Telcon, Inc. (“Telcon”) which were acquired in July 2017 for ₩36,001,446,221 KRW (equivalent to $31.8 million USD) at ₩5,419 KRW per share. As of March 31, 2019 and December 31, 2018, the closing prices per CellSeed share on the Tokyo Stock Exchange were ¥710 ($6.40 USD) and ¥668 JPY ($6.07 USD), respectively, and the closing prices per Telcon share on the Korean Securities Dealers Automated Quotations (“KOSDAQ”) were ₩7,350 ($6.45 USD) and ₩8,280 KRW ($7.43 USD), respectively. As of March 31, 2019, and December 31, 2018, 39,250 shares of CellSeed common stock were pledged to secure a $300,000 convertible note of the Company issued to Mitsubishi UFJ Capital III Limited Partnership that is due on demand and were classified as marketable securities, pledged to creditor in our balance sheet. Prepaid expenses and other current assets — Prepaid expenses and other current assets consisted of the following at March 31, 2019 and December 31, 2018 (in thousands): March 31, 2019 December 31, 2018 Prepaid insurance $ 80 $ 82 Other prepaid expenses and current assets 738 661 $ 818 $ 743 Other long-term liabilities —Other long-term liabilities consisted of the following at March 31, 2019 and December 31, 2018 (in thousands): March 31, 2019 December 31, 2018 Trade discount $ 25,137 $ 26,222 Unearned revenue 10,500 10,000 Other long-term liabilities — — Total other long-term liabilities $ 35,637 $ 36,222 The Company entered into an API Supply Agreement (the “API Agreement”) with Telcon pursuant to which Telcon advanced to the Company approximately ₩36.0 billion KRW (approximately $31.8 million USD), accounted for as a trade discount, in consideration for the right to supply 25% of the Company’s requirements for bulk containers of pharmaceutical grade L-glutamine (“PGLG”). Refer Note 10 for additional details. Fair value measurements — The following table presents the change in fair value of warrant derivative liabilities on a recurring basis using Level 3 inputs during the year ended December 31, 2018 (in thousands): Year Ended Warrant Derivative Liabilities—Stock Purchase Warrants December 31, 2018 Balance, beginning of period $ 26,377 Repurchased (6,186 ) Change in fair value included in the statement of comprehensive income (loss) (20,191 ) Balance, end of period $ — The following table presents the change in fair value of warrants issued to GPB Debt Holdings II, LLC as described in Note 8 as of March 31, 2019 and December 31, 2018 (in thousands): For the Three Months Ended Year Ended March 31, 2019 December 31, 2018 Warrant Derivative Liabilities—GPB Warrants Embedded Conversion Option Warrants Embedded Conversion Option Balance, beginning of period $ 1,399 $ — $ 1,882 $ 1,289 Fair value at issuance date — — — — Change in fair value included in the statement of comprehensive income (loss) 48 — (483 ) (466 ) Extinguished upon debt repayment — — — (823 ) Balance, end of period $ 1,447 $ — $ 1,399 $ — The value of warrant derivative liabilities and the change in fair value of the warrant derivative liabilities were determined using a Binomial Monte-Carlo Cliquet (aka “Ratchet”) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models, except that the exercise price resets at certain dates in the future. The value as of the dates set forth in the table above, was based on upon following assumptions: March 31, 2019 December 31, 2018 Stock price $ 10.30 $ 9.10 Risk‑free interest rate 2.22 % 2.48 % Expected volatility (peer group) 70.00 % 70.00 % Expected life (in years) 3.75 4.00 Expected dividend yield — — Number outstanding 240,764 240,764 Balance, end of period: Warrant derivative liabilities (long-term) (in thousands) $ 1,447 $ 1,399 Debt and related party debt — The following table presents the effective interest rates on loans originated and refinanced in the respective periods that either had a beneficial conversion feature or an attached warrant: Type of Loan Term of Loan Stated Annual Interest Original Loan Principal Amount Conversion Rate Beneficial Conversion Discount Amount Warrants Issued with Notes Exercise Price Warrant FMV Discount Amount Effective Interest Rate Including Discounts 2017 convertible notes payable Due on demand - 2 years 10% $ 5,795 $3.50-$10.00 $ 1,545 $ — N/A N/A 25% - 110% 2018 convertible notes payable Due on demand - 2 years 10% 24,135 $3.50-$10.00 10,266 — — — 10%-110% 2019 convertible notes payable Due on demand - 1 year 10% 2,039 $3.50-$4.50 2,039 — — — 110% 2018 notes payable 18 months 10% 12,200 N/A — 1,220,000 $ 11.30 9,687 89% $ 44,169 $ 13,850 $ 1,220,000 $ 9,687 Related party notes are reflected as a separate line items in the Company’s consolidated balance sheets. Net loss per share — As of March 31, 2019 and 2018, respectively, the Company had outstanding potentially dilutive securities exercisable for or convertible into 16,317,940 and 17,122,176 shares of Company common stock. No potentially dilutive securities were included in the calculation of diluted net loss per share since their effect would be anti-dilutive for all periods presented. Recent accounting pronouncements —In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . The ASU amendments applicable to the Company (1) supersede the guidance to classify equity securities, except equity method securities, with readily determinable fair values into trading or available-for-sale categories and require equity securities to be measured at fair value with changes in the fair value recognized through net income, (2) allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment, (3) require assessment for impairment of equity investments without readily determinable fair values qualitatively at each reporting period, (4) eliminate the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet, (5) require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, (6) require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements, (7) clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. This ASU was effective beginning January 1, 2018. Since then, the Company has recognized any changes in the fair value of certain equity investments in net income as prescribed by the new standard rather than in other comprehensive income. The Company recognized a cumulative effect adjustment to increase the opening balance of retained earnings as of January 1, 2018 by $41.4 million, net of $12.3 million income tax benefit. Refer to Note 5 for additional disclosures required by this ASU. In February 2016, the FASB issued ASU No. 2016-02, Leases Targeted Improvements In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In February 2018, the FASB issued ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities Fair Value Measurement Derivatives and Hedging— Embedded Derivatives Financial Instruments— Overall In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement accompanying footnote disclosures In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810) Targeted Improvements to Related Party guidance for Variable Interest Entities (“ASU 2018-17”) Interest Held Through Related Parties That Are Under Common Control.

REVENUES

REVENUES	3 Months Ended
	Mar. 31, 2019
Revenue From Contract With Customer [Abstract]
REVENUES	NOTE 3 — REVENUES Revenues disaggregated by category were as follows (in thousands): Three months ended March 31, 2019 March 31, 2018 Endari $ 5,787 $ 720 Other 105 102 Gross sales 5,892 822 Less: discounts and allowances Endari (585 ) (30 ) Other — (11 ) Total $ 5,307 $ 781 The following table summarizes the revenue allowance and accrual activities for the three months ended March 31, 2019 (in thousands): Trade Discounts, Allowances and Chargebacks Government Rebates and Other Incentives Returns Total Balance as of December 31, 2018 $ 303 $ 1,880 $ 181 $ 2,363 Provision related to sales in the current year 293 729 54 1,076 Adjustments related prior period sales — (600 ) — (600 ) Credit and payments made (316 ) (568 ) — (884 ) Balance as of March 31, 2019 $ 279 $ 1,441 $ 235 $ 1,955 The following table summarizes revenues attributable to each of our customers who accounted for 10% or more of our total revenues (as a percentage of total revenues): Three months ended March 31, 2019 March 31, 2018 AmerisourceBergen Specialty Group 60 % 88 % McKesson Plasma and Biologics LLC 17 % —

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	3 Months Ended
	Mar. 31, 2019
Property Plant And Equipment [Abstract]
PROPERTY AND EQUIPMENT	NOTE 4 — PROPERTY AND EQUIPMENT Property and equipment consisted of the following (in thousands): March 31, 2019 December 31, 2018 Equipment $ 306 $ 306 Leasehold improvements 71 70 Furniture and fixtures 79 79 Total property and equipment 456 455 Less: accumulated depreciation (317 ) (303 ) Total depreciable assets 139 152 Construction-in-progress 14 — Property and equipment, net $ 153 $ 152 During the three months ended March 31, 2019 and 2018, depreciation expense was approximately $14,000 and $13,000, respectively.

INVESTMENTS

INVESTMENTS	3 Months Ended
	Mar. 31, 2019
Investments [Abstract]
INVESTMENTS	NOTE 5 — INVESTMENTS Equity Securities— Effective January 1, 2018, the Company adopted ASU 2016-01 which requires the Company to measure all equity investments that do not result in consolidation and are not accounted for under the equity method at fair value and recognize in earnings any changes in such fair value. The Company uses quoted market prices to determine the fair value of equity securities with readily determinable fair values. For equity securities without readily determinable fair values, the Company has elected the measurement alternative under which the Company measures these investments at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Management assesses each of these investments on an individual basis. Additionally, on a quarterly basis, management is required to make a qualitative assessment of whether the investment is impaired; however, the Company is not required to determine the fair value of these investments unless impairment indicators existed. When impairment indicators exist, the Company generally uses discounted cash flow analyses to determine the fair value. For the three months ended March 31, 2019 and the year ended December 31, 2018, the Company did not recognize any fair value adjustments for equity securities without readily determinable fair values. The Company recognized a cumulative effect adjustment of $41.4 million, net of $12.3 million income tax benefit, to increase the opening balance of retained earnings with an offset to accumulated other comprehensive income as of January 1, 2018, in connection with the adoption of ASU 2016-01. At March 31, 2019 and December 31, 2018, the carrying values of equity securities were included in the following line items in our consolidated balance sheets (in thousands): March 31, 2019 December 31, 2018 Fair Value with Changes Recognized in Income Measurement Alternative - No Readily Determinable Fair Value Fair Value with Changes Recognized in Income Measurement Alternative - No Readily Determinable Fair Value Marketable securities $ 43,124 $ — $ 49,581 $ — Long-term investment at cost — 527 — 538 Total equity securities $ 43,124 $ 527 $ 49,581 $ 538 Net realized losses on available-for-sales on marketable securities still held at March 31, 2019 was approximately $ 6.5 million and net realized gain on available-for sales on marketable securities still held at March 31, 2018 was approximately $ 5.5 million.

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2019
Payables And Accruals [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	NOTE 6 — ACCOUNTS PAYABLE AND ACCRUED EXPENSES At March 31, 2019 and December 31, 2018, accounts payable and accrued expenses consisted of the following (in thousands): March 31, 2019 December 31, 2018 Accounts payable: Clinical and regulatory expenses $ 356 $ 83 Professional fee 1,961 2,157 Selling expenses 421 382 Manufacturing costs 1,756 — Other vendors 692 980 Total accounts payable 5,186 3,602 Accrued interest payable, related parties 1,217 842 Accrued interest payable 2,306 2,138 Accrued expenses: Payroll expenses 796 713 Accrued rebates 1,441 1,744 Other accrued expenses 122 83 Total accrued expenses 2,359 2,540 Total accounts payable and accrued expenses $ 11,068 $ 9,122

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 — NOTES PAYABLE Notes payable consisted of the following at March 31, 2019 and December 31, 2018 (in thousands): Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding March 31, 2019 Discount Amount March 31, 2019 Carrying Amount March 31, 2019 Shares Underlying Notes March 31, 2019 Principal Outstanding December 31, 2018 Discount Amount December 31, 2018 Carrying Amount December 31, 2018 Shares Underlying Notes December 31, 2018 Notes payable 2013 10% Due on demand — $ 902 $ — $ 902 — $ 909 $ — $ 909 — 2015 10% Due on demand — 10 — 10 — 10 — 10 — 2016 10% - 11% Due on demand — 843 — 843 — 843 — 843 — 2017 5% - 11% Due on demand — 1,951 — 1,951 — 2,575 — 2,575 — 2018 10% - 11% Due on demand- 18 months — 12,311 7,847 4,464 — 12,311 9,233 3,078 — 2019 11% Due on demand — 752 — 752 — — — — — $ 16,769 $ 7,847 $ 8,922 — $ 16,648 $ 9,233 $ 7,415 — Current $ 14,569 $ 7,569 $ 7,000 — $ 12,449 $ 6,054 $ 6,394 — Non-current $ 2,200 $ 278 $ 1,922 — $ 4,200 $ 3,179 $ 1,021 — Notes payable - related party 2016 10% Due on demand — 270 — 270 — 270 — 270 — 2017 10% Due on demand — 27 — 27 — 39 — 39 — 2018 11% Due on demand — 159 — 159 — 159 — 159 — 2019 10% Due on demand — 14 — 14 — — — — — $ 470 $ — $ 470 — $ 468 $ — $ 468 — Current $ 470 $ — $ 470 — $ 468 $ — $ 468 — Non-current $ — $ — $ — — $ — $ — $ — — Convertible notes payable 2011 10% 5 years $3.05 $ 300 $ — $ 300 98 $ 300 $ — $ 300 98 2014 10% Due on demand - 2 years $3.05 - $3.60 522 — 522 186 519 — 519 184 2016 10% Due on demand - 2 years $3.60 - $4.50 62 — 62 17 61 — 61 17 2017 10% - 13.5% Due on demand - 3 years $3.50 - $10.31 1,895 108 1,787 618 2,820 349 2,471 899 2018 6% - 10% Due on demand - 2 years $3.50 - $10.00 15,311 2,671 12,640 3,076 19,556 6,169 13,387 3,664 2019 10% Due on demand - 1 year $3.50 - $4.50 2,039 1,804 235 570 — — — — $ 20,129 $ 4,583 $ 15,546 4,565 $ 23,256 $ 6,518 $ 16,738 4,862 Current $ 19,421 $ 4,264 $ 15,157 4,402 $ 16,604 $ 5,351 $ 11,253 3,981 Non-current $ 708 $ 319 $ 389 163 $ 6,652 $ 1,167 $ 5,485 881 Convertible notes payable - related party 2012 10% Due on demand $ 3.30 $ 200 $ — $ 200 76 $ 200 $ — $ 200 74 2015 10% 2 years $ 4.50 200 — 200 59 200 — 200 58 2017 10% 2 years $ 10.00 5,000 218 4,782 545 5,000 311 4,689 533 2018 10% 2 years $ 10.00 9,400 686 8,714 995 9,400 871 8,529 972 $ 14,800 $ 904 $ 13,896 1,675 $ 14,800 $ 1,182 $ 13,618 1,637 Current $ 14,800 $ 904 $ 13,896 1,675 $ 5,400 $ 311 $ 5,089 665 Non-current $ — $ — $ — — $ 9,400 $ 871 $ 8,529 972 Total $ 52,168 $ 13,334 $ 38,834 6,240 $ 55,172 $ 16,933 $ 38,239 6,499 The weighted-average stated interest rates of notes payable were 10% as of each of March 31, 2019 and December 31, 2018. weighted average effective interest rates of notes payable as of March 31, 2019 and December 31, 2018 were 48% and 35% respectively, after giving effect to discounts relating to beneficial conversion features and the fair value of warrants issued in connection with these notes. The notes payable and convertible notes payable contain no restrictive financial covenants or acceleration clauses associated with a material adverse change event. The holders of the convertible notes have the option to convert their notes into Company common stock at conversion prices ranging $3.05 to $10.00 per share during the terms of the notes. Certain notes with a $4.50 or a $10.00 stated conversion price in the second year of their two-year term are subject to automatic conversion into shares of Company common stock at a conversion price equal to 80% of the initial public offering price at the time of a qualified public offering. All notes due on demand are treated as current liabilities. During the three months ended March 31, 2019, the Company proposed to the holders of its outstanding convertible promissory notes to amend the terms thereof to provide for an automatic conversion into shares of Company common stock at their respective conversion prices immediately prior to the effective time of the proposed merger transaction with MYnd Analytics, Inc. As such, the conversion shares would be deemed outstanding immediately prior to the merger and would be converted into shares of MYnd Analytics, Inc. common stock as a result of the merger in the same manner as other outstanding shares of Company common stock based the merger “exchange ratio.” As of March 31, 2019, the holders of an aggregate of $4.8 million, or 14%, in principal amount of the outstanding convertible notes, had agreed to the amendment. See Note 12 for information regarding the amendment of additional convertible notes subsequent to March 31, 2019. Contractual principal payments due on notes payable are as follows: Year Ending 2019 (nine months) $ 31,703 2020 20,465 Total $ 52,168 The Company estimated the total fair value of any beneficial conversion feature and accompanying warrants in allocating the note proceeds. The proceeds allocated to the beneficial conversion feature were determined by taking the estimated fair value of shares issuable under the convertible notes less the fair value of the number of shares that would be issued if the conversion rate equaled the fair value of Company common stock as of the date of issuance (see Note 2). The fair value of the warrants issued in conjunction with notes was determined using the Binominal Monte-Carlo Cliquet Option Pricing Model with the following inputs for the year ended December 31, 2018. Year ended December 31, 2018 Stock price $ 11.10 Exercise price $ 11.30 Term 5 years Risk‑free interest rate 3.05 % Expected dividend yield — Expected volatility 70.0 % With respect to the notes that included both a beneficial conversion feature and a warrant, the proceeds were allocated to the beneficial conversion feature and the warrant based on their respective pro rata fair values. The Company did not issue any notes with warrants notes in the three months ended March 31, 2019.

STOCKHOLDERS' DEFICIT

STOCKHOLDERS' DEFICIT	3 Months Ended
	Mar. 31, 2019
Stockholders Equity Note [Abstract]
STOCKHOLDERS' DEFICIT	NOTE 8 — STOCKHOLDERS’ DEFICIT Private placement — On September 11, 2013, the Company issued an aggregate of 3,020,501 units at a price of $2.50 per unit (the “Private Placement”). Each unit consisted of one share of common stock and one common stock warrant for the purchase of an additional share of common stock. The aggregate purchase price for the units was approximately $7.6 million. In addition, 300,000 warrants for the purchase of a share of common stock were issued to a broker under the same terms as the Private Placement transaction (the “Broker Warrants”). The warrants issued in the Private Placement and the Broker Warrants entitle the holders thereof to purchase, at any time on or prior to September 11, 2018, shares of common stock of the Company at an exercise price of $3.50 per share. The warrants contain non-standard anti-dilution protection and, consequently, are being accounted for as liabilities, were originally recorded at fair value, and are adjusted to fair market value each reporting period. Because the shares of common stock underlying the Private Placement warrants and Broker Warrants were not effectively registered for resale by September 11, 2014, the warrant holders have an option to exercise the warrants using a cashless exercise feature. The shares have not been registered for resale as of September 30, 2018. The availability to warrant holders of the cashless exercise feature as of September 11, 2014 caused the then-outstanding 2,225,036 Private Placement warrants and Broker Warrants with fair value of approximately $7.1 million to be reclassified from liability classified warrants to warrant derivative liabilities and to continue to be remeasured at fair value each reporting period. On June 10, 2014, certain warrant holders exercised 1,095,465 warrants issued in the Private Placement for the exercise price of $3.50 per share, resulting in the Company receiving aggregate exercise proceeds of $3.8 million and issuing 1,095,465 shares of common stock. Prior to exercise, these Private Placement warrants were accounted for at fair value as liability classified warrants. As of June 10, 2014, immediately prior to exercise, the carrying value of these Private Placement warrants was reduced to their fair value of $1.8 million, representing their intrinsic value, with this adjusted carrying value of $1.8 million being transferred to additional paid-in capital. Also on June 10, 2014, based on an offer made to holders of Private Placement warrants in connection with such exercises, the Company issued an aggregate of 1,095,465 replacement warrants to holders exercising Private Placement warrants, which replacement warrants have terms that are generally the same as the exercised warrants, including an expiration date of September 11, 2018 and an exercise price of $3.50 per share. The replacement warrants are treated for accounting purposes as liability classified warrants, and their issuance gave rise to a $3.5 million warrant exercise inducement expense based on their fair value as of issuance as determined using a Binomial Monte-Carlo Cliquet (aka Ratchet) Option Pricing Model. Because the shares of common stock underlying the replacement warrants were not effectively registered for resale by June 10, 2015, the warrant holders have an option to exercise the warrants using a cashless exercise feature. The availability to warrant holders of the cashless exercise feature as of June 10, 2015 caused the then-outstanding 1,095,465 replacement warrants with fair value of approximately $2.5 million to be reclassified from liability classified warrants to warrant derivative liabilities and to continue to be remeasured at fair value each reporting period. As of September 11, 2018, all of the Private Placement warrants, replacement warrants and Broker Warrants had been exercised primarily on a cashless basis or had expired. Purchase Agreement with GPB —On December 29, 2017, the Company entered into the Purchase Agreement with GPB Debt Holdings II, LLC (“GPB”), pursuant to which the Company issued to GPB a $13 million principal amount senior secured convertible promissory note (the “GPB Note”) for an aggregate purchase price of approximately $12.5 million, which reflected a 4.0% original issue discount. In connection with the issuance of the GPB Note, the Company also issued to GPB a warrant (the “GPB Warrant to purchase up to 240,674 of Company common stock at an exercise price of $10.80 per company share, with customary adjustments for stock splits, stock dividends and other recapitalization events and anti-dilution provisions set forth in the GPB Warrant. If the Company effects a public listing of common stock for trading on any securities market or exchange, whether through a direct listing application or merger transaction, at a price per share less than the exercise price, the exercise price will be adjusted on a one-time basis to a 10% premium to the dilutive issuance price and the number of shares issuable under the GPB Warrant will be increased on a full ratchet basis. The GPB Warrant became exercisable six months after issuance and has a term of five years after the initial exercise date. In connection with the Purchase Agreement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) pursuant to which the Company has agreed to file a registration statement with SEC relating to the offer and sale by GPB of the common stock underlying the GPB Warrant within one hundred eighty (180) days of closing of a public listing of the Company’s Common Stock for trading on any national securities exchange (excluding any over-the-counter market), whether through a direct listing application or merger transaction. The Company is required to have the registration statement become effective on the earlier of (A) the date that is two-hundred and forty (240) days following the later to occur of (i) the date of closing of the public listing or (ii) or in the event the registration statement receives a “full review” by the Commission, the date that is 300 days following the date of closing of the public listing, or (B) the date which is within three (3) business days after the date on which the Commission informs the Company (i) that the Commission will not review the registration statement or (ii) that the Company may request the acceleration of the effectiveness of the registration statement. If the Company does not timely effect such registration, it will be required to pay GPB certain late payments specified in the Registration Rights Agreement. In February 2018, the Company prepaid the GPB Note in full. Upon such prepayment, the Purchase Agreement and the Company’s obligations under the transaction documents entered into pursuant to the Purchase Agreement terminated except for the GPB Warrant and the Registration Rights Agreement. In October 2018, the Company sold and issued $12.2 million principal amount of debentures and warrants to purchase an aggregate of up to 1,220,000 share of the Company common stock pursuant to a securities purchase agreement dated as of September 18, 2018 among the Company and limited number of accredited investors. The net proceeds of the sale of the debentures and warrants were used to fund the Company’s loan to EJ Holdings, Inc., a variable interest entity (“VIE”)reflected in the Company’s consolidated financial statements. The debentures bear interest at the rate of 10% per annum, payable monthly commencing November 1, 2018, and will mature on April 21, 2020. The Company will be obliged to redeem $1 million principal amount debentures monthly, commencing in May 2019, which was amended to commence in June 2019 pursuant to securities amendment agreement dated as of March 5, 2019, and to redeem the debentures in full upon a “subsequent financing” of at least $20 million, subject to certain exceptions, or in the “event of default” (as defined). The Company’s obligations under the debentures are secured by a security interest in substantially all of our assets, except for certain pledged marketable securities and are guaranteed by the U.S. subsidiaries, Emmaus Medical, Inc. and Newfield Nutrition Corporation. The common stock purchase warrants are exercisable for five years beginning April 22, 2019 at an initial exercise price of $11.30 per share, which will be subject to reduction if we become a listed company or our common stock becomes listed or quoted on a trading market based upon the public offering price or “VWAP” of the Company common stock. The exercise price also will be subject to adjustment in certain other customary circumstances. T.R. Winston & Company, LLC acted as placement agent in connection with the sales of the debentures and warrants pursuant to an amended and restated fee agreement with us dated October 1, 2018. In accordance with the fee agreement, the Company paid T.R. Winston a cash fee equal to 5% of the gross proceeds received from the purchasers granted T.R. Winston warrants to purchase up to 120,000 shares of the Company common stock on the same terms as the common stock purchase warrants sold to the purchasers and reimbursed T.R. Winston for certain legal fees and expenses. Effective as of March 5, 2019, the Company entered into a securities amendment agreement with the debenture holders related warrants which provides that the securities purchase agreement among the Company and the holders of the debentures and warrants is to be amended in certain respects, and the debentures and warrants are to be amended in certain respects and restated in their entirety, immediately prior to and subject to the completion of our proposed merger transaction with MYnd Analytics, Inc. described in our Current Report on Form 8-K filed with the Securities and Exchange Commission on January 7, 2019. Pursuant to the terms of the securities amendment agreement, (i) the debenture holders waived their right to the monthly redemption of $1,000,000 principal amount of the debentures that was due May 1, 2019 and their right to accelerate the repayment of the debentures in connection with the proposed merger transaction and (iii) the provision of the debentures requiring their mandatory redemption in connection with any “subsequent financing” was eliminated. If the merger does not occur, the securities amendment agreement will have no effect, except as described in this paragraph. If issued in conjunction with the proposed merger transaction, the amended and restated debentures will provide that the monthly redemption of $1,000,000 principal amount thereof will commence in November 2019 and that they will mature on October 21, 2020, six months later than the current maturity date of the debentures. Unlike the debentures, the amended and restated debentures will be convertible at the option of each holder into shares of Company common stock at a conversion price of $10 a share, subject to adjustment for stock splits and other customary events. The amended and restated warrants will be exercisable for up to an aggregate of up to 1,460,000 shares of our common stock, or 240,000 more shares than are currently purchasable under the warrants, at an initial exercise price of $10.00 per share, or $1.30 less than the current exercise price of the warrants. The exercise price of the Warrants will be subject to reduction in connection with a “going public event,” which we expect to occur in conjunction with the proposed merger, based upon the public offering price if the Company completes a bona fide public offering or the “VWAP” (i.e., volume-weighted average trading price) of MYnd Analytics, Inc. (which will change its name to Emmaus Life Sciences, Inc. in conjunction with the merger) common stock at the time of the merger. The exercise price of the amended and restated warrants also will be subject to reduction pursuant to a “full-ratchet” exercise-price antidilution adjustment in the event of a sale or issuance of common stock or common stock equivalents within 60 days following the merger at an effective price per share below the exercise price of the amended and restated warrants. The exercise price also will be subject to adjustment for stock splits and other customary events. The amended and restated debentures and amended and restated warrants will be assumed by the ongoing company following the proposed merger and become convertible and exercisable for the number of shares of common stock of the ongoing company and at a conversion price and exercise price based upon the “exchange ratio” in the merger. The original securities purchase agreement entitles the holders of the warrants to registration rights with respect to the shares issuable upon exercise of the warrants. The securities amendment agreement extends the same rights to the shares issuable upon conversion of the amended and restated debentures, as well. A summary of outstanding warrants as of March 31, 2019 and December 31, 2018 is presented below: Three Months Ended Year Ended March 31, 2019 December 31, 2018 Warrants outstanding, beginning of period 3,436,431 5,265,432 Granted — 1,542,000 Exercised (500 ) (2,385,317 ) Cancelled, forfeited and expired — (985,684 ) Warrants outstanding, end of period 3,435,931 3,436,431 A summary of outstanding warrants by year issued and exercise price as of March 31, 2019 is presented below: Outstanding Exercisable Year issued and Exercise Price Number of Warrants Issued Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Total Weighted Average Exercise Price At December 31, 2014 $ 3.50 50,000 0.08 $ 3.50 50,000 $ 3.50 2014 Total 50,000 50,000 At December 31, 2015 $ 4.90 110,417 0.93 $ 4.90 110,417 $ 4.90 2015 Total 110,417 110,417 At December 31, 2016 $ 4.50 118,750 2.25 $ 4.50 118,750 $ 4.50 $ 4.70 75,000 2.09 $ 4.70 75,000 $ 4.70 $ 5.00 1,300,000 2.11 $ 5.00 1,300,000 $ 5.00 2016 Total 1,493,750 1,493,750 At December 31, 2017 $ 10.80 240,764 4.25 $ 10.80 240,764 $ 10.80 2017 Total 240,764 240,764 At December 31, 2018 $ 11.30 1,541,000 4.54 $ 11.30 1,541,000 $ 11.30 2018 Total 1,541,000 1,541,000 At March 31, 2019 Total 3,435,931 3,435,931 Stock options — During the year ended December 31, 2018, the Company’s Board of Directors granted its officers, directors and employees stock options to purchase up to 357,000 shares of Company’s common stock. The options will vest and become exercisable with respect to the underlying shares as follows: as to one‑third (1/3) of the share on the first anniversary of the grant date, and as to the remaining two‑thirds (2/3) of the shares in twenty‑four (24) approximately equal monthly installments over a period of two years thereafter . Summaries of outstanding stock options as of March 31, 2019 and December 31, 2018 are presented below. March 31, 2019 December 31, 2018 Number of Options Weighted‑ Average Exercise Price Number of Options Weighted‑ Average Exercise Price Options outstanding, beginning of period 6,642,200 $ 4.40 6,775,200 $ 4.12 Granted or deemed issued — $ — 357,000 $ 11.28 Exercised (200 ) $ 5.00 (170,000 ) $ 4.59 Cancelled, forfeited and expired — $ — (320,000 ) $ 6.06 Options outstanding, end of period 6,642,000 $ 4.40 6,642,200 $ 4.40 Options exercisable, end of period 6,153,778 $ 4.01 5,958,783 $ 3.87 Options available for future grant 2,358,000 2,357,800 During the three months ended March 31, 2019 and 2018, the Company recognized approximately $0.5 million and $0.7 million, respectively, of share-based compensation expense arising from stock options. As of March 31, 2019, there was approximately $2.1 million of total unrecognized compensation expense related to unvested share-based compensation arrangements granted under the Company’s 2011 Stock Incentive Plan. That expense is expected to be recognized over the weighted-average remaining period of 2.2 years. Registration rights — See Note 8 regarding registration rights relating to shares of Company common stock underlying warrant issued to GPB on December 29, 2017. Korean Private Placement — On September 12, 2016, the Company entered into Letter of Agreement with KPM and Hanil, both Korean-based public companies whose shares are listed on KOSDAQ, a trading board of Korea Exchange in South Korea. In the Letter of Agreement, the parties agreed that KPM and Hanil would purchase $17.0 million and $3.0 million, respectively, of shares of the Company’s common stock at a price of $4.50 per share. In exchange, the Company agreed to invest $13.0 million and $1.0 million in future capital increases by KPM and Hanil, respectively, at prices based upon the trading prices of KPM and Hanil shares on KOSDAQ. In connection with the Letter of Agreement, KPM and Hanil entered into the Company’s standard form subscription agreement with respect to their purchase of shares which contains customary representations and warranties of the parties On September 29, 2016, KPM and Hanil purchased from the Company 3,777,778 shares and 666,667 shares, respectively, of common stock at a price of $4.50 a share for $17 million and $3 million, respectively, or a total of $20.0 million. The Company recognized $720,000 as a reduction to its additional paid-in-capital for fees and commissions paid by the Company in connection with the transaction. The Company invested $13.0 million and $1.0 million in capital increases by KPM and Hanil, respectively, at $15.32 and $3.68, respectively, per capital share.

LEASES

LEASES	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
LEASES	NOTE 9 — LEASES Operating leases — The Company leases its office space under operating leases with unrelated entities. We lease 13,734 square feet of office space for our headquarters in Torrance, California, at a base rental of $48,087 per month. In December 2018, we have entered into an amended lease to expand our headquarter by an additional 7,559 square feet commencing June 1, 2019. The base monthly rent for this additional space of $27,590 will be payable commencing January 1, 2020. The amended lease will expire on May 31, 2026. We also lease an additional 1,600 square feet office space in Torrance, California, at a base rent of $2,240 per month and 2,986 square feet office space in New York, New York, at a base rent of $5,500, which leases will expire on January 31, 2020 and December 30, 2019, respectively. In addition, we lease 1,322 square feet of office space in Tokyo, Japan, which the lease will expire on September 30, 2020. Rent expense during the three months ended March 31, 2019 and 2018 amounted to approximately $201,000 and $124,000, respectively. Future minimum lease payments under the agreements were as follows as of March 31, 2019 (in thousands): Amount 2019 (nine months) 547 2020 980 2021 975 2022 1,003 2023 and thereafter 3,665 Total lease payments 7,170 Less: Interest 4,010 Present value of lease liabilities 3,160 The weighted average remaining lease term is 6.9 years and the weighted average discount rate is 13.8%.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 10 — COMMITMENTS AND CONTINGENCIES Management Control Acquisition Agreement — On June 12, 2017, the Company entered into a Management Control Acquisition Agreement (the “MCAA”) with Telcon Holdings, Inc., a Korean corporation, and Telcon Inc., a Korean-based public company whose shares are listed on KOSDAQ, a trading board of Korea Exchange in South Korea. In accordance with the MCAA, the Company invested the ₩36.0 billion KRW (approximately $31.8 million USD) proceeds from the advance payment by Telcon Inc. under the API Supply Agreement discussed below to purchase 6,643,559 shares of Telcon Inc’s common shares at a purchase price of ₩5,419 KRW (approximately $4.79 USD) per share. The MCAA was amended in certain respect and supplemented by an Agreement, dated as of September 29, 2017 (the “September 2017 Agreement”), among the parties. Pursuant to the Agreement, among other things, Telcon Inc. purchased 4,444,445 shares of Company common stock from KPM and Hanil at a price of $6.60 per share. On July 2, 2018, the Company entered into an Additional Agreement with Evercore Investment Holdings Co., Ltd. (formerly Telcon Holdings Co., Ltd.) (“Evercore”) and Telcon RF Pharmaceutical Inc. (formerly Telcon Inc.). In the Additional Agreement, the Company agreed to use the proceeds from any sales of the Company’s KPM shares to repurchase shares of Company common stock from Telcon RF Pharmaceutical, Inc at a price of $7.60 a share, subject to certain exceptions, and Telcon RF Pharmaceutical Inc. granted the Company the right to repurchase all or a portion of Telcon RF Pharmaceutical Inc.’s shares of Company common stock at a price of $7.60 a share until October 31, 2018 and at a price to be agreed upon after October 31, 2018. In the Additional Agreement, Telcon RF Pharmaceutical Inc. also granted the Company a right of first refusal until June 30, 2019 to purchase any of the Company shares that Telcon RF Pharmaceutical Inc. may wish to sell. Raw Material Supply Agreement — On June 12, 2017, the Company entered into an API Supply Agreement with Telcon RF Pharmaceutical Inc pursuant to which it advanced to the Company approximately ₩36.0 billion KRW (approximately $31.8 million USD) in consideration of the right to supply 25% of the Company’s requirements for bulk containers of PGLG for a term to fifteen (15) years. The amount advanced to the Company was recorded as a deferred Trade Discount. On July 12, 2017, the parties entered into a Raw Material Supply Agreement which superseded the API Supply Agreement. The Raw Material Supply Agreement is effective for a term of five (5) years with ten (10) one-year renewal periods. The Raw Material Supply Agreement will automatically renew unless terminated by either party in writing. The Raw Material Supply Agreement provides that the Company will purchase from Telcon RF Pharmaceutical Inc. 940,000 kilograms of PGLG at $50 USD per kilogram, or a total of $47.0 million. The PGLG purchased from Telcon is included in inventory at net realizable value (i.e., approximately $189 per kilogram as of March 31, 2019) with the excess purchase price being recorded as a charge against the deferred Trade Discount.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 11 — RELATED PARTY TRANSACTIONS The following table sets forth information relating to our loans from related persons outstanding or at any time during the three months ended March 31, 2019 (in thousands): Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at March 31, 2019 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes March 31, 2019 Current, Promissory note payable to related parties: Lan T. Tran (2) 10% 4/29/2016 Due on Demand 20 20 — — — — Hope Hospice (1) 10% 6/3/2016 Due on Demand 250 250 — — — — Lan T. Tran (2) 10% 2/9/2017 Due on Demand — 12 — — — — Yutaka Niihara (2)(3) 10% 9/14/2017 Due on Demand 27 904 — — — — Lan T. Tran (2) 10% 2/10/2018 Due on Demand 159 159 — — — — Lan T. Tran (2) 10% 2/9/2019 Due on Demand 14 14 — — — — Subtotal $ 470 $ 1,359 $ — $ — — Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10% 6/29/2012 Due on Demand $ 200 $ 200 $ — $ — $ 3.30 76 Yutaka & Soomi Niihara (2)(3) 10% 11/16/2015 2 years 200 200 — — $ 4.50 59 Wei Peu Zen (3) 10% 11/6/2017 2 years 5,000 5,000 — 250 $ 10.00 545 Profit Preview International Group, Ltd. (4) 10% 2/1/2018 2 years 4,037 4,037 — 202 $ 10.00 430 Profit Preview International Group, Ltd. (4) 10% 3/21/2018 2 years 5,363 5,363 — 268 $ 10.00 565 Subtotal $ 14,800 $ 14,800 $ — $ — 1,675 Total $ 15,270 $ 16,159 $ — $ — 1,675 (1) Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice. (2) Officer. (3) Director. (4) Mr. Zen, a Director of the Company, is the sole owner of Profit Preview International Group, Ltd. The following table sets forth information relating to our loans from related persons outstanding at any time during the year ended December 31, 2018: Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2018 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes December 31, 2018 Current, Promissory note payable to related parties: Masaharu & Emiko Osato (3) 11 % 12/29/2015 Due on Demand $ — $ 300 $ 300 $ 76 — — Lan T. Tran (2) 11 % 2/10/2016 Due on Demand — 131 131 29 — — Masaharu & Emiko Osato (3) 11 % 2/25/2016 Due on Demand — 400 400 94 — — Lan T. Tran (2) 10 % 4/29/2016 Due on Demand 20 20 — — — — Hope Hospice (1) 10 % 6/3/2016 Due on Demand 250 250 — — — — Lan T. Tran (2) 10 % 2/9/2017 Due on Demand 12 12 — — — — Yutaka Niihara (2)(3) 10 % 9/14/2017 Due on Demand 27 904 877 95 — — Lan T. Tran (2) 11 % 2/10/2018 Due on Demand 159 159 — — — — Subtotal $ 468 $ 2,176 $ 1,708 $ 294 — Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10 % 6/29/2012 Due on Demand 200 200 — — $ 3.30 74 Yutaka & Soomi Niihara (2)(3) 10 % 11/16/2015 2 years 200 200 — — $ 4.50 58 Wei Peu Zen (3) 10 % 11/6/2017 2 years 5,000 5,000 — 250 $ 10.00 533 Subtotal $ 5,400 $ 5,400 $ — $ 250 665 Non Current, Convertible notes payable to related parties: Profit Preview International Group, Ltd. (4) 10 % 2/1/2018 2 years 4,037 4,037 — 202 $ 10.00 420 Profit Preview International Group, Ltd. (4) 10 % 3/21/2018 2 years 5,363 5,363 — 268 $ 10.00 552 Subtotal $ 9,400 $ 9,400 $ — $ 470 972 Total $ 15,268 $ 16,976 $ 1,708 $ 1,014 1,637 (1) Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice. (2) Officer (3) Director ( 4 ) Mr. Zen, a Director of the Company, is the sole owner of Profit Preview International Group, Ltd.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 12 — SUBSEQUENT EVENTS As discussed in Note 7, as of March 31, 2019 the Company had entered into amendments with the holders of an aggregate of $4.8 million, or 14%, in principal amount of the Company’s outstanding convertible notes which provide that the notes will be converted automatically into shares of Company common stock at their respective conversion prices immediately prior to the effective time of the proposed merger transaction with MYnd Analytics, Inc. As such, the conversion shares would be deemed outstanding immediately prior to the merger and would be converted into shares of MYnd Analytics, Inc. common stock as a result of the merger in the same manner as other outstanding shares of Company common stock based the merger “exchange ratio.” As of May 14, 2019, the holders of a total of an additional $4.2 million, or 12%, in principal amount of the outstanding convertible notes had also agreed to the amendment. The Company intends to continue discussions regarding the same or similar amendments with the holders of the remaining outstanding convertible notes. There is no assurance that the Company will be able to do so on the same terms, or at all. Subsequent to March 31, 2019, the Company issued the following: Amounts Number of Shares Issued Common shares $ 711,550 103,590

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Revenues	Revenues – Effective January 1, 2018, the Company adopted Accounting Standard codification (“ASC”) Topic 606, Revenue from Contracts with Customers using the modified retrospective transition methods. The adoption of ASC 606 did not have a material impact on the measurement or on the recognition of revenue of contracts for which all revenue had not been recognized as of January 1, 2018, therefore no cumulative adjustment has been made to the opening balance of accumulated deficit at the beginning of 2018. The comparative information has not been restated and continues to be reported under the accounting standards in effect for the periods presented. Since January 2018, the Company has generated revenues through the sale of Endari as a treatment for sickle cell disease (“SCD”). The Company also generates revenues to a much lesser extent from the sale of AminoPure®, a nutritional supplement. Revenues from Endari product sales are recognized upon delivery and transfer of control of products to the Company’s distributors and specialty pharmacy customers. Distributors resell the products to other specialty pharmacy providers, health care providers, hospitals, patients and clinics. In addition to distribution agreements with distributors, the Company enters into contractual arrangements with specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities that provide for government-mandated or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of our products. These various discounts, rebates, and charge-backs are referred to as “variable consideration.” Revenues from product sales are recorded net of variable consideration. Prior to recognizing revenues, the Company’s management forecasts and estimates variable consideration. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenues recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. Provisions for returns and other variable consideration adjustments are provided for in the period in which the related revenues are recorded. Actual amounts of consideration ultimately received may differ from our estimates. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known. The following are our significant categories of sales discounts and allowances: Sales Discounts: The Company provides its customers contractual prompt payment discounts and from time to time offers additional one-time discounts that are recorded as a reduction of revenues in the period the revenues are recognized. Product Returns: The Company offers its distributors a right to return product purchased directly from the Company based principally upon (i) overstocks, (ii) inactive product or non-moving product due to market conditions, and (iii) expired products. Product return allowances are estimated and recorded at the time of sale. Government Rebates: The Company is subject to discount obligations under state Medicaid programs and the Medicare prescription drug coverage gap program. The Company’s management estimates Medicaid and Medicare prescription drug coverage gap rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenues are recognized, resulting in a reduction of product revenues and the establishment of a current liability that is included as accounts payable and accrued expenses in our balance sheet. The liability for these rebates consists primarily of estimates of claims expected to be received in future periods related to the recognized revenues. Chargebacks and Discounts: Chargebacks for fees and discounts represent the estimated obligations resulting from contractual commitments to sell products to certain specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities at prices lower than the list prices charged to distributors. The distributors charge the Company for the difference between what they pay for the products and the Company’s contracted selling price to these specialty pharmacy providers, in-office dispensing providers, group purchasing organizations, and government entities. These reserves are established in the same period that the related revenues are recognized, resulting in a reduction of revenues. Chargeback amounts are generally determined at the time of resale of products by the distributors.
Leases	— As described below under "Recent accounting pronouncements Prior to our adoption of ASU 2016-02, when our lease agreements contained tenant improvement allowances and rent escalation clauses, we recorded a deferred rent asset or liability equal to the difference between the rent expense and the future minimum lease payments due. The lease expense related to operating leases was recognized on a straight-line basis in the statements of operations over the term of each lease. In cases where the lessor granted us leasehold improvement allowances, we capitalized the improvements as incurred and recognized it over the shorter of the lease term or the expected useful life of the improvements.
Inventories	Inventories — Substantially all of the raw material purchased during the three months ended March 31, 2019 and for the year ended December 31, 2018 were from one vendor. The below table presents inventory by category (in thousands): Inventories by category March 31, 2019 December 31, 2018 Raw materials and components $ 647 $ 171 Work-in-process 1,584 2,471 Finished goods 3,564 2,063 Total $ 5,795 $ 4,705
Marketable securities	Marketable securities — The Company’s marketable securities consist of the following securities; (a) 39,250 shares of capital stock of CellSeed, Inc. (“CellSeed”) acquired in January 2009 at ¥680 JPY per share ($7.69 USD); (b) 6,643,559 shares of capital stock of Telcon, Inc. (“Telcon”) which were acquired in July 2017 for ₩36,001,446,221 KRW (equivalent to $31.8 million USD) at ₩5,419 KRW per share. As of March 31, 2019 and December 31, 2018, the closing prices per CellSeed share on the Tokyo Stock Exchange were ¥710 ($6.40 USD) and ¥668 JPY ($6.07 USD), respectively, and the closing prices per Telcon share on the Korean Securities Dealers Automated Quotations (“KOSDAQ”) were ₩7,350 ($6.45 USD) and ₩8,280 KRW ($7.43 USD), respectively. As of March 31, 2019, and December 31, 2018, 39,250 shares of CellSeed common stock were pledged to secure a $300,000 convertible note of the Company issued to Mitsubishi UFJ Capital III Limited Partnership that is due on demand and were classified as marketable securities, pledged to creditor in our balance sheet.
Prepaid expenses and other current assets	Prepaid expenses and other current assets — Prepaid expenses and other current assets consisted of the following at March 31, 2019 and December 31, 2018 (in thousands): March 31, 2019 December 31, 2018 Prepaid insurance $ 80 $ 82 Other prepaid expenses and current assets 738 661 $ 818 $ 743
Other long-term liabilities	Other long-term liabilities —Other long-term liabilities consisted of the following at March 31, 2019 and December 31, 2018 (in thousands): March 31, 2019 December 31, 2018 Trade discount $ 25,137 $ 26,222 Unearned revenue 10,500 10,000 Other long-term liabilities — — Total other long-term liabilities $ 35,637 $ 36,222 The Company entered into an API Supply Agreement (the “API Agreement”) with Telcon pursuant to which Telcon advanced to the Company approximately ₩36.0 billion KRW (approximately $31.8 million USD), accounted for as a trade discount, in consideration for the right to supply 25% of the Company’s requirements for bulk containers of pharmaceutical grade L-glutamine (“PGLG”). Refer Note 10 for additional details.
Fair value measurements	Fair value measurements — The following table presents the change in fair value of warrant derivative liabilities on a recurring basis using Level 3 inputs during the year ended December 31, 2018 (in thousands): Year Ended Warrant Derivative Liabilities—Stock Purchase Warrants December 31, 2018 Balance, beginning of period $ 26,377 Repurchased (6,186 ) Change in fair value included in the statement of comprehensive income (loss) (20,191 ) Balance, end of period $ — The following table presents the change in fair value of warrants issued to GPB Debt Holdings II, LLC as described in Note 8 as of March 31, 2019 and December 31, 2018 (in thousands): For the Three Months Ended Year Ended March 31, 2019 December 31, 2018 Warrant Derivative Liabilities—GPB Warrants Embedded Conversion Option Warrants Embedded Conversion Option Balance, beginning of period $ 1,399 $ — $ 1,882 $ 1,289 Fair value at issuance date — — — — Change in fair value included in the statement of comprehensive income (loss) 48 — (483 ) (466 ) Extinguished upon debt repayment — — — (823 ) Balance, end of period $ 1,447 $ — $ 1,399 $ — The value of warrant derivative liabilities and the change in fair value of the warrant derivative liabilities were determined using a Binomial Monte-Carlo Cliquet (aka “Ratchet”) Option Pricing Model. The model is similar to traditional Black-Scholes-type option pricing models, except that the exercise price resets at certain dates in the future. The value as of the dates set forth in the table above, was based on upon following assumptions: March 31, 2019 December 31, 2018 Stock price $ 10.30 $ 9.10 Risk‑free interest rate 2.22 % 2.48 % Expected volatility (peer group) 70.00 % 70.00 % Expected life (in years) 3.75 4.00 Expected dividend yield — — Number outstanding 240,764 240,764 Balance, end of period: Warrant derivative liabilities (long-term) (in thousands) $ 1,447 $ 1,399
Debt and related party debt	Debt and related party debt — The following table presents the effective interest rates on loans originated and refinanced in the respective periods that either had a beneficial conversion feature or an attached warrant: Type of Loan Term of Loan Stated Annual Interest Original Loan Principal Amount Conversion Rate Beneficial Conversion Discount Amount Warrants Issued with Notes Exercise Price Warrant FMV Discount Amount Effective Interest Rate Including Discounts 2017 convertible notes payable Due on demand - 2 years 10% $ 5,795 $3.50-$10.00 $ 1,545 $ — N/A N/A 25% - 110% 2018 convertible notes payable Due on demand - 2 years 10% 24,135 $3.50-$10.00 10,266 — — — 10%-110% 2019 convertible notes payable Due on demand - 1 year 10% 2,039 $3.50-$4.50 2,039 — — — 110% 2018 notes payable 18 months 10% 12,200 N/A — 1,220,000 $ 11.30 9,687 89% $ 44,169 $ 13,850 $ 1,220,000 $ 9,687 Related party notes are reflected as a separate line items in the Company’s consolidated balance sheets.
Net loss per share	Net loss per share — As of March 31, 2019 and 2018, respectively, the Company had outstanding potentially dilutive securities exercisable for or convertible into 16,317,940 and 17,122,176 shares of Company common stock. No potentially dilutive securities were included in the calculation of diluted net loss per share since their effect would be anti-dilutive for all periods presented.
Recent accounting pronouncements	Recent accounting pronouncements —In January 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities . The ASU amendments applicable to the Company (1) supersede the guidance to classify equity securities, except equity method securities, with readily determinable fair values into trading or available-for-sale categories and require equity securities to be measured at fair value with changes in the fair value recognized through net income, (2) allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment, (3) require assessment for impairment of equity investments without readily determinable fair values qualitatively at each reporting period, (4) eliminate the requirement to disclose the methods and significant assumptions used in calculating the fair value of financial instruments required to be disclosed for financial instruments measured at amortized cost on the balance sheet, (5) require public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes, (6) require separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements, (7) clarify that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. This ASU was effective beginning January 1, 2018. Since then, the Company has recognized any changes in the fair value of certain equity investments in net income as prescribed by the new standard rather than in other comprehensive income. The Company recognized a cumulative effect adjustment to increase the opening balance of retained earnings as of January 1, 2018 by $41.4 million, net of $12.3 million income tax benefit. Refer to Note 5 for additional disclosures required by this ASU. In February 2016, the FASB issued ASU No. 2016-02, Leases Targeted Improvements In April 2016, the FASB issued ASU 2016-10, Revenue from Contracts with Customers (Topic 606): Identifying Performance Obligations and Licensing In July 2017, the FASB issued ASU No. 2017-11, Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815): I. Accounting for Certain Financial Instruments with Down Round Features, II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). In February 2018, the FASB issued ASU No. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income In February 2018, the FASB issued ASU No. 2018-03, Technical Corrections and Improvements to Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities Fair Value Measurement Derivatives and Hedging— Embedded Derivatives Financial Instruments— Overall In June 2018, the FASB issued ASU No. 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement accompanying footnote disclosures In October 2018, the FASB issued ASU 2018-17, Consolidation (Topic 810) Targeted Improvements to Related Party guidance for Variable Interest Entities (“ASU 2018-17”) Interest Held Through Related Parties That Are Under Common Control.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of inventory	The below table presents inventory by category (in thousands): Inventories by category March 31, 2019 December 31, 2018 Raw materials and components $ 647 $ 171 Work-in-process 1,584 2,471 Finished goods 3,564 2,063 Total $ 5,795 $ 4,705
Schedule of prepaid expenses and other current assets	Prepaid expenses and other current assets consisted of the following at March 31, 2019 and December 31, 2018 (in thousands): March 31, 2019 December 31, 2018 Prepaid insurance $ 80 $ 82 Other prepaid expenses and current assets 738 661 $ 818 $ 743
Schedule of other long-term liabilities	Other long-term liabilities consisted of the following at March 31, 2019 and December 31, 2018 (in thousands): March 31, 2019 December 31, 2018 Trade discount $ 25,137 $ 26,222 Unearned revenue 10,500 10,000 Other long-term liabilities — — Total other long-term liabilities $ 35,637 $ 36,222
Schedule of change in fair value of warrant derivative liabilities	The following table presents the change in fair value of warrant derivative liabilities on a recurring basis using Level 3 inputs during the year ended December 31, 2018 (in thousands): Year Ended Warrant Derivative Liabilities—Stock Purchase Warrants December 31, 2018 Balance, beginning of period $ 26,377 Repurchased (6,186 ) Change in fair value included in the statement of comprehensive income (loss) (20,191 ) Balance, end of period $ —
Schedule of change in fair value of warrants issued to GPB Debt Holdings II, LLC	The following table presents the change in fair value of warrants issued to GPB Debt Holdings II, LLC as described in Note 8 as of March 31, 2019 and December 31, 2018 (in thousands): For the Three Months Ended Year Ended March 31, 2019 December 31, 2018 Warrant Derivative Liabilities—GPB Warrants Embedded Conversion Option Warrants Embedded Conversion Option Balance, beginning of period $ 1,399 $ — $ 1,882 $ 1,289 Fair value at issuance date — — — — Change in fair value included in the statement of comprehensive income (loss) 48 — (483 ) (466 ) Extinguished upon debt repayment — — — (823 ) Balance, end of period $ 1,447 $ — $ 1,399 $ —
Schedule of assumptions used in the valuation of warrants	The value as of the dates set forth in the table above, was based on upon following assumptions: March 31, 2019 December 31, 2018 Stock price $ 10.30 $ 9.10 Risk‑free interest rate 2.22 % 2.48 % Expected volatility (peer group) 70.00 % 70.00 % Expected life (in years) 3.75 4.00 Expected dividend yield — — Number outstanding 240,764 240,764 Balance, end of period: Warrant derivative liabilities (long-term) (in thousands) $ 1,447 $ 1,399
Schedule of notes payable with beneficial conversion feature or warrants	The following table presents the effective interest rates on loans originated and refinanced in the respective periods that either had a beneficial conversion feature or an attached warrant: Type of Loan Term of Loan Stated Annual Interest Original Loan Principal Amount Conversion Rate Beneficial Conversion Discount Amount Warrants Issued with Notes Exercise Price Warrant FMV Discount Amount Effective Interest Rate Including Discounts 2017 convertible notes payable Due on demand - 2 years 10% $ 5,795 $3.50-$10.00 $ 1,545 $ — N/A N/A 25% - 110% 2018 convertible notes payable Due on demand - 2 years 10% 24,135 $3.50-$10.00 10,266 — — — 10%-110% 2019 convertible notes payable Due on demand - 1 year 10% 2,039 $3.50-$4.50 2,039 — — — 110% 2018 notes payable 18 months 10% 12,200 N/A — 1,220,000 $ 11.30 9,687 89% $ 44,169 $ 13,850 $ 1,220,000 $ 9,687

REVENUES (Tables)

REVENUES (Tables)	3 Months Ended
	Mar. 31, 2019
Revenue From Contract With Customer [Abstract]
Summary of revenues disaggregated by category	Revenues disaggregated by category were as follows (in thousands): Three months ended March 31, 2019 March 31, 2018 Endari $ 5,787 $ 720 Other 105 102 Gross sales 5,892 822 Less: discounts and allowances Endari (585 ) (30 ) Other — (11 ) Total $ 5,307 $ 781
Revenue Allowance and Accrual Activities	The following table summarizes the revenue allowance and accrual activities for the three months ended March 31, 2019 (in thousands): Trade Discounts, Allowances and Chargebacks Government Rebates and Other Incentives Returns Total Balance as of December 31, 2018 $ 303 $ 1,880 $ 181 $ 2,363 Provision related to sales in the current year 293 729 54 1,076 Adjustments related prior period sales — (600 ) — (600 ) Credit and payments made (316 ) (568 ) — (884 ) Balance as of March 31, 2019 $ 279 $ 1,441 $ 235 $ 1,955
Summarizes revenues from each of our customers accounted for 10% or more of total revenues	The following table summarizes revenues attributable to each of our customers who accounted for 10% or more of our total revenues (as a percentage of total revenues): Three months ended March 31, 2019 March 31, 2018 AmerisourceBergen Specialty Group 60 % 88 % McKesson Plasma and Biologics LLC 17 % —

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	3 Months Ended
	Mar. 31, 2019
Property Plant And Equipment [Abstract]
Schedule of property and equipment	Property and equipment consisted of the following (in thousands): March 31, 2019 December 31, 2018 Equipment $ 306 $ 306 Leasehold improvements 71 70 Furniture and fixtures 79 79 Total property and equipment 456 455 Less: accumulated depreciation (317 ) (303 ) Total depreciable assets 139 152 Construction-in-progress 14 — Property and equipment, net $ 153 $ 152

INVESTMENTS (Tables)

INVESTMENTS (Tables)	3 Months Ended
	Mar. 31, 2019
Investments [Abstract]
Schedule of carrying values of equity securities	At March 31, 2019 and December 31, 2018, the carrying values of equity securities were included in the following line items in our consolidated balance sheets (in thousands): March 31, 2019 December 31, 2018 Fair Value with Changes Recognized in Income Measurement Alternative - No Readily Determinable Fair Value Fair Value with Changes Recognized in Income Measurement Alternative - No Readily Determinable Fair Value Marketable securities $ 43,124 $ — $ 49,581 $ — Long-term investment at cost — 527 — 538 Total equity securities $ 43,124 $ 527 $ 49,581 $ 538

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2019
Payables And Accruals [Abstract]
Schedule of accounts payable and accrued expenses	At March 31, 2019 and December 31, 2018, accounts payable and accrued expenses consisted of the following (in thousands): March 31, 2019 December 31, 2018 Accounts payable: Clinical and regulatory expenses $ 356 $ 83 Professional fee 1,961 2,157 Selling expenses 421 382 Manufacturing costs 1,756 — Other vendors 692 980 Total accounts payable 5,186 3,602 Accrued interest payable, related parties 1,217 842 Accrued interest payable 2,306 2,138 Accrued expenses: Payroll expenses 796 713 Accrued rebates 1,441 1,744 Other accrued expenses 122 83 Total accrued expenses 2,359 2,540 Total accounts payable and accrued expenses $ 11,068 $ 9,122

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
Schedule of notes payable	Notes payable consisted of the following at March 31, 2019 and December 31, 2018 (in thousands): Year Issued Interest Rate Range Term of Notes Conversion Price Principal Outstanding March 31, 2019 Discount Amount March 31, 2019 Carrying Amount March 31, 2019 Shares Underlying Notes March 31, 2019 Principal Outstanding December 31, 2018 Discount Amount December 31, 2018 Carrying Amount December 31, 2018 Shares Underlying Notes December 31, 2018 Notes payable 2013 10% Due on demand — $ 902 $ — $ 902 — $ 909 $ — $ 909 — 2015 10% Due on demand — 10 — 10 — 10 — 10 — 2016 10% - 11% Due on demand — 843 — 843 — 843 — 843 — 2017 5% - 11% Due on demand — 1,951 — 1,951 — 2,575 — 2,575 — 2018 10% - 11% Due on demand- 18 months — 12,311 7,847 4,464 — 12,311 9,233 3,078 — 2019 11% Due on demand — 752 — 752 — — — — — $ 16,769 $ 7,847 $ 8,922 — $ 16,648 $ 9,233 $ 7,415 — Current $ 14,569 $ 7,569 $ 7,000 — $ 12,449 $ 6,054 $ 6,394 — Non-current $ 2,200 $ 278 $ 1,922 — $ 4,200 $ 3,179 $ 1,021 — Notes payable - related party 2016 10% Due on demand — 270 — 270 — 270 — 270 — 2017 10% Due on demand — 27 — 27 — 39 — 39 — 2018 11% Due on demand — 159 — 159 — 159 — 159 — 2019 10% Due on demand — 14 — 14 — — — — — $ 470 $ — $ 470 — $ 468 $ — $ 468 — Current $ 470 $ — $ 470 — $ 468 $ — $ 468 — Non-current $ — $ — $ — — $ — $ — $ — — Convertible notes payable 2011 10% 5 years $3.05 $ 300 $ — $ 300 98 $ 300 $ — $ 300 98 2014 10% Due on demand - 2 years $3.05 - $3.60 522 — 522 186 519 — 519 184 2016 10% Due on demand - 2 years $3.60 - $4.50 62 — 62 17 61 — 61 17 2017 10% - 13.5% Due on demand - 3 years $3.50 - $10.31 1,895 108 1,787 618 2,820 349 2,471 899 2018 6% - 10% Due on demand - 2 years $3.50 - $10.00 15,311 2,671 12,640 3,076 19,556 6,169 13,387 3,664 2019 10% Due on demand - 1 year $3.50 - $4.50 2,039 1,804 235 570 — — — — $ 20,129 $ 4,583 $ 15,546 4,565 $ 23,256 $ 6,518 $ 16,738 4,862 Current $ 19,421 $ 4,264 $ 15,157 4,402 $ 16,604 $ 5,351 $ 11,253 3,981 Non-current $ 708 $ 319 $ 389 163 $ 6,652 $ 1,167 $ 5,485 881 Convertible notes payable - related party 2012 10% Due on demand $ 3.30 $ 200 $ — $ 200 76 $ 200 $ — $ 200 74 2015 10% 2 years $ 4.50 200 — 200 59 200 — 200 58 2017 10% 2 years $ 10.00 5,000 218 4,782 545 5,000 311 4,689 533 2018 10% 2 years $ 10.00 9,400 686 8,714 995 9,400 871 8,529 972 $ 14,800 $ 904 $ 13,896 1,675 $ 14,800 $ 1,182 $ 13,618 1,637 Current $ 14,800 $ 904 $ 13,896 1,675 $ 5,400 $ 311 $ 5,089 665 Non-current $ — $ — $ — — $ 9,400 $ 871 $ 8,529 972 Total $ 52,168 $ 13,334 $ 38,834 6,240 $ 55,172 $ 16,933 $ 38,239 6,499
Schedule of contractual principal payments of notes payable	Contractual principal payments due on notes payable are as follows: Year Ending 2019 (nine months) $ 31,703 2020 20,465 Total $ 52,168
Schedule of fair value assumptions for warrants issued in conjunction with notes	The fair value of the warrants issued in conjunction with notes was determined using the Binominal Monte-Carlo Cliquet Option Pricing Model with the following inputs for the year ended December 31, 2018. Year ended December 31, 2018 Stock price $ 11.10 Exercise price $ 11.30 Term 5 years Risk‑free interest rate 3.05 % Expected dividend yield — Expected volatility 70.0 %

STOCKHOLDERS' DEFICIT (Tables)

STOCKHOLDERS' DEFICIT (Tables)	3 Months Ended
	Mar. 31, 2019
Stockholders Equity Note [Abstract]
Schedule of outstanding warrants	A summary of outstanding warrants as of March 31, 2019 and December 31, 2018 is presented below: Three Months Ended Year Ended March 31, 2019 December 31, 2018 Warrants outstanding, beginning of period 3,436,431 5,265,432 Granted — 1,542,000 Exercised (500 ) (2,385,317 ) Cancelled, forfeited and expired — (985,684 ) Warrants outstanding, end of period 3,435,931 3,436,431 A summary of outstanding warrants by year issued and exercise price as of March 31, 2019 is presented below: Outstanding Exercisable Year issued and Exercise Price Number of Warrants Issued Weighted Average Remaining Contractual Life (Years) Weighted Average Exercise Price Total Weighted Average Exercise Price At December 31, 2014 $ 3.50 50,000 0.08 $ 3.50 50,000 $ 3.50 2014 Total 50,000 50,000 At December 31, 2015 $ 4.90 110,417 0.93 $ 4.90 110,417 $ 4.90 2015 Total 110,417 110,417 At December 31, 2016 $ 4.50 118,750 2.25 $ 4.50 118,750 $ 4.50 $ 4.70 75,000 2.09 $ 4.70 75,000 $ 4.70 $ 5.00 1,300,000 2.11 $ 5.00 1,300,000 $ 5.00 2016 Total 1,493,750 1,493,750 At December 31, 2017 $ 10.80 240,764 4.25 $ 10.80 240,764 $ 10.80 2017 Total 240,764 240,764 At December 31, 2018 $ 11.30 1,541,000 4.54 $ 11.30 1,541,000 $ 11.30 2018 Total 1,541,000 1,541,000 At March 31, 2019 Total 3,435,931 3,435,931
Schedule of stock option activity	Summaries of outstanding stock options as of March 31, 2019 and December 31, 2018 are presented below. March 31, 2019 December 31, 2018 Number of Options Weighted‑ Average Exercise Price Number of Options Weighted‑ Average Exercise Price Options outstanding, beginning of period 6,642,200 $ 4.40 6,775,200 $ 4.12 Granted or deemed issued — $ — 357,000 $ 11.28 Exercised (200 ) $ 5.00 (170,000 ) $ 4.59 Cancelled, forfeited and expired — $ — (320,000 ) $ 6.06 Options outstanding, end of period 6,642,000 $ 4.40 6,642,200 $ 4.40 Options exercisable, end of period 6,153,778 $ 4.01 5,958,783 $ 3.87 Options available for future grant 2,358,000 2,357,800

LEASES (Tables)

LEASES (Tables)	3 Months Ended
	Mar. 31, 2019
Leases [Abstract]
Schedule of future minimum lease payments	Future minimum lease payments under the agreements were as follows as of March 31, 2019 (in thousands): Amount 2019 (nine months) 547 2020 980 2021 975 2022 1,003 2023 and thereafter 3,665 Total lease payments 7,170 Less: Interest 4,010 Present value of lease liabilities 3,160

RELATED PARTY TRANSACTIONS (Tab

RELATED PARTY TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Schedule of outstanding loans from related parties	The following table sets forth information relating to our loans from related persons outstanding or at any time during the three months ended March 31, 2019 (in thousands): Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at March 31, 2019 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes March 31, 2019 Current, Promissory note payable to related parties: Lan T. Tran (2) 10% 4/29/2016 Due on Demand 20 20 — — — — Hope Hospice (1) 10% 6/3/2016 Due on Demand 250 250 — — — — Lan T. Tran (2) 10% 2/9/2017 Due on Demand — 12 — — — — Yutaka Niihara (2)(3) 10% 9/14/2017 Due on Demand 27 904 — — — — Lan T. Tran (2) 10% 2/10/2018 Due on Demand 159 159 — — — — Lan T. Tran (2) 10% 2/9/2019 Due on Demand 14 14 — — — — Subtotal $ 470 $ 1,359 $ — $ — — Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10% 6/29/2012 Due on Demand $ 200 $ 200 $ — $ — $ 3.30 76 Yutaka & Soomi Niihara (2)(3) 10% 11/16/2015 2 years 200 200 — — $ 4.50 59 Wei Peu Zen (3) 10% 11/6/2017 2 years 5,000 5,000 — 250 $ 10.00 545 Profit Preview International Group, Ltd. (4) 10% 2/1/2018 2 years 4,037 4,037 — 202 $ 10.00 430 Profit Preview International Group, Ltd. (4) 10% 3/21/2018 2 years 5,363 5,363 — 268 $ 10.00 565 Subtotal $ 14,800 $ 14,800 $ — $ — 1,675 Total $ 15,270 $ 16,159 $ — $ — 1,675 (1) Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice. (2) Officer. (3) Director. (4) Mr. Zen, a Director of the Company, is the sole owner of Profit Preview International Group, Ltd. The following table sets forth information relating to our loans from related persons outstanding at any time during the year ended December 31, 2018: Class Lender Interest Rate Date of Loan Term of Loan Principal Amount Outstanding at December 31, 2018 Highest Principal Outstanding Amount of Principal Repaid or Converted into Stock Amount of Interest Paid Conversion Rate Shares Underlying Notes December 31, 2018 Current, Promissory note payable to related parties: Masaharu & Emiko Osato (3) 11 % 12/29/2015 Due on Demand $ — $ 300 $ 300 $ 76 — — Lan T. Tran (2) 11 % 2/10/2016 Due on Demand — 131 131 29 — — Masaharu & Emiko Osato (3) 11 % 2/25/2016 Due on Demand — 400 400 94 — — Lan T. Tran (2) 10 % 4/29/2016 Due on Demand 20 20 — — — — Hope Hospice (1) 10 % 6/3/2016 Due on Demand 250 250 — — — — Lan T. Tran (2) 10 % 2/9/2017 Due on Demand 12 12 — — — — Yutaka Niihara (2)(3) 10 % 9/14/2017 Due on Demand 27 904 877 95 — — Lan T. Tran (2) 11 % 2/10/2018 Due on Demand 159 159 — — — — Subtotal $ 468 $ 2,176 $ 1,708 $ 294 — Current, Convertible notes payable to related parties: Yasushi Nagasaki (2) 10 % 6/29/2012 Due on Demand 200 200 — — $ 3.30 74 Yutaka & Soomi Niihara (2)(3) 10 % 11/16/2015 2 years 200 200 — — $ 4.50 58 Wei Peu Zen (3) 10 % 11/6/2017 2 years 5,000 5,000 — 250 $ 10.00 533 Subtotal $ 5,400 $ 5,400 $ — $ 250 665 Non Current, Convertible notes payable to related parties: Profit Preview International Group, Ltd. (4) 10 % 2/1/2018 2 years 4,037 4,037 — 202 $ 10.00 420 Profit Preview International Group, Ltd. (4) 10 % 3/21/2018 2 years 5,363 5,363 — 268 $ 10.00 552 Subtotal $ 9,400 $ 9,400 $ — $ 470 972 Total $ 15,268 $ 16,976 $ 1,708 $ 1,014 1,637 (1) Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice. (2) Officer (3) Director ( 4 ) Mr. Zen, a Director of the Company, is the sole owner of Profit Preview International Group, Ltd.

SUBSEQUENT EVENTS (Tables)

SUBSEQUENT EVENTS (Tables)	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Schedule of subsequent events	Subsequent to March 31, 2019, the Company issued the following: Amounts Number of Shares Issued Common shares $ 711,550 103,590

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

Jan. 01, 2019USD ($)

Jul. 31, 2018USD ($)

Jan. 01, 2018USD ($)

Jun. 12, 2017USD ($)$ / shares

Jun. 12, 2017KRW (₩)₩ / shares

Jul. 31, 2017USD ($)shares

Jul. 31, 2017KRW (₩)₩ / sharesshares

Jan. 31, 2009$ / shares

Jan. 31, 2009¥ / shares

Mar. 31, 2019USD ($)Vendor$ / sharesshares

Mar. 31, 2018USD ($)

Dec. 31, 2018USD ($)Vendor$ / sharesshares

Mar. 31, 2019¥ / shares

Mar. 31, 2019₩ / shares

Dec. 31, 2018¥ / shares

Dec. 31, 2018₩ / shares

Summary of Significant Accounting Policy [Line Items]

Number of vendors | Vendor

1

1

Potentially dilutive securities outstanding | shares

16,317,940

17,122,176

Operating lease liabilities

$ 3,160,000

Lease right-of-use asset

2,838,000

Deferred rent

201,000

$ 124,000

ASU 2016-01 [Member]

Summary of Significant Accounting Policy [Line Items]

Cumulative effect adjustment on adoption of ASU

$ 41,400,000

41,400,000

Cumulative effect on retained earnings, tax

$ 12,300,000

12,300,000

ASU 2016-02 [Member]

Summary of Significant Accounting Policy [Line Items]

Cumulative effect adjustment on adoption of ASU

$ (29,000)

(29,000)

Operating lease liabilities

$ 3,200,000

Lease right-of-use asset

2,900,000

Deferred rent

$ 286,000

2011 Convertible notes payable [Member]

Summary of Significant Accounting Policy [Line Items]

Convertible notes payable, carrying amount

$ 300,000

$ 300,000

CellSeed, Inc. [Member]

Summary of Significant Accounting Policy [Line Items]

Shares held as marketable securities | shares

39,250

Investment, in per share | (per share)

$ 7.69

¥ 680

Investment, closing price | (per share)

$ 6.40

$ 6.07

¥ 710

¥ 668

Stock pledged against note | shares

39,250

39,250

Telcon, Inc. ("Telcon") [Member]

Summary of Significant Accounting Policy [Line Items]

Shares held as marketable securities | shares

6,643,559

6,643,559

Investment, in per share | ₩ / shares

₩ 5,419

Investment

$ 31,800,000

₩ 36,001,446,221

Investment, closing price | (per share)

$ 6.45

$ 7.43

₩ 7,350

₩ 8,280

Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member]

Summary of Significant Accounting Policy [Line Items]

Investment, closing price | $ / shares

$ 4.79

Proceeds from supply agreement

$ 31,800,000

Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member] | Korea (South), Won

Summary of Significant Accounting Policy [Line Items]

Investment, in per share | ₩ / shares

₩ 5,419

Proceeds from supply agreement | ₩

₩ 36,000,000,000

Telcon, Inc. ("Telcon") [Member] | API Supply Agreement [Member] | Pharmaceutical Grade L-glutamine [Member]

Summary of Significant Accounting Policy [Line Items]

Percentage of right to supply

25.00%

25.00%

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 1) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Inventories by category
Raw materials and components	$ 647	$ 171
Work-in-process	1,584	2,471
Finished goods	3,564	2,063
Total	$ 5,795	$ 4,705

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Prepaid insurance	$ 80	$ 82
Other prepaid expenses and current assets	738	661
Prepaid expenses and other current assets	$ 818	$ 743

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Summary of Significant Accounting Policy [Line Items]
Other long-term liabilities	$ 35,637	$ 36,222
Unearned Revenue [Member]
Summary of Significant Accounting Policy [Line Items]
Other long-term liabilities	10,500	10,000
Trade Discount [Member]
Summary of Significant Accounting Policy [Line Items]
Other long-term liabilities	$ 25,137	$ 26,222

SUMMARY OF SIGNIFICANT ACCOUN_8

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 4) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Warrant Derivative Liabilities - Stock Purchase Warrants [Member] | Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period		$ 26,377
Repurchased		(6,186)
Change in fair value included in the statement of comprehensive income (loss)		(20,191)
Derivative Liabilities - Warrants [Member] | GPB Debt Holdings II, LLC [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period	$ 1,399	1,882
Change in fair value included in the statement of comprehensive income (loss)	48	(483)
Balance, end of period	$ 1,447	1,399
Warrant Derivative Liabilities - Embedded Conversion Option [Member] | GPB Debt Holdings II, LLC [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance, beginning of period		1,289
Change in fair value included in the statement of comprehensive income (loss)		(466)
Extinguished upon debt repayment		$ (823)

SUMMARY OF SIGNIFICANT ACCOUN_9

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 5) $ / shares in Units, $ in Thousands	Mar. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares
Summary of Significant Accounting Policy [Line Items]
Stock price | $ / shares	$ 10.30	$ 9.10
Number outstanding | shares	240,764	240,764
Warrant derivative liabilities (long-term) | $	$ 1,447	$ 1,399
Measurement Input, Risk Free Interest Rate
Summary of Significant Accounting Policy [Line Items]
Warrants and rights outstanding, measurement input	2.22	2.48
Measurement Input, Price Volatility
Summary of Significant Accounting Policy [Line Items]
Warrants and rights outstanding, measurement input	70	70
Measurement Input, Expected Term
Summary of Significant Accounting Policy [Line Items]
Expected life (in years)	3 years 9 months	4 years

SUMMARY OF SIGNIFICANT ACCOU_10

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 6)	3 Months Ended
	Mar. 31, 2019USD ($)$ / shares$ / Warrantshares
Summary of Significant Accounting Policy [Line Items]
Original Loan Principal Amount	$ 44,169
Beneficial Conversion Discount Amount	$ 13,850
Warrants Issued with Notes (in shares) | shares	1,220,000
Warrant FMV Discount Amount	$ 9,687
Minimum [Member]
Summary of Significant Accounting Policy [Line Items]
Conversion Rate (in dollars per share) | $ / shares	$ 3.05
Maximum [Member]
Summary of Significant Accounting Policy [Line Items]
Conversion Rate (in dollars per share) | $ / shares	$ 10
2017 Convertible Notes Payable [Member]
Summary of Significant Accounting Policy [Line Items]
Stated Annual Interest	10.00%
Original Loan Principal Amount	$ 5,795
Beneficial Conversion Discount Amount	$ 1,545
2017 Convertible Notes Payable [Member] | Minimum [Member]
Summary of Significant Accounting Policy [Line Items]
Term of Loan	Due on demand
Conversion Rate (in dollars per share) | $ / shares	$ 3.50
Effective Interest Rate Including Discounts	25.00%
2017 Convertible Notes Payable [Member] | Maximum [Member]
Summary of Significant Accounting Policy [Line Items]
Term of Loans	2 years
Conversion Rate (in dollars per share) | $ / shares	$ 10
Effective Interest Rate Including Discounts	110.00%
2018 Convertible Notes Payable [Member]
Summary of Significant Accounting Policy [Line Items]
Stated Annual Interest	10.00%
Original Loan Principal Amount	$ 24,135
Beneficial Conversion Discount Amount	$ 10,266
2018 Convertible Notes Payable [Member] | Minimum [Member]
Summary of Significant Accounting Policy [Line Items]
Term of Loan	Due on demand
Stated Annual Interest	6.00%
Conversion Rate (in dollars per share) | $ / shares	$ 3.50
Effective Interest Rate Including Discounts	10.00%
2018 Convertible Notes Payable [Member] | Maximum [Member]
Summary of Significant Accounting Policy [Line Items]
Term of Loans	2 years
Stated Annual Interest	10.00%
Conversion Rate (in dollars per share) | $ / shares	$ 10
Effective Interest Rate Including Discounts	110.00%
2019 Convertible Notes Payable [Member]
Summary of Significant Accounting Policy [Line Items]
Stated Annual Interest	10.00%
Original Loan Principal Amount	$ 2,039
Beneficial Conversion Discount Amount	$ 2,039
Effective Interest Rate Including Discounts	110.00%
2019 Convertible Notes Payable [Member] | Minimum [Member]
Summary of Significant Accounting Policy [Line Items]
Term of Loan	Due on demand
Conversion Rate (in dollars per share) | $ / shares	$ 3.50
2019 Convertible Notes Payable [Member] | Maximum [Member]
Summary of Significant Accounting Policy [Line Items]
Term of Loans	1 year
Conversion Rate (in dollars per share) | $ / shares	$ 4.50
Notes Payable 2018 [Member]
Summary of Significant Accounting Policy [Line Items]
Term of Loans	18 months
Stated Annual Interest	10.00%
Original Loan Principal Amount	$ 12,200
Warrants Issued with Notes (in shares) | shares	1,220,000
Exercise Price (in dollars per share) | $ / Warrant	11.30
Warrant FMV Discount Amount	$ 9,687
Effective Interest Rate Including Discounts	89.00%

REVENUES (Details)

REVENUES (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Disaggregation Of Revenue [Line Items]
Gross sales	$ 5,892	$ 822
Total	5,307	781
Endari [Member]
Disaggregation Of Revenue [Line Items]
Gross sales	5,787	720
Discounts and allowances	(585)	(30)
Other [Member]
Disaggregation Of Revenue [Line Items]
Gross sales	$ 105	102
Discounts and allowances		$ (11)

REVENUES (Details 1)

REVENUES (Details 1) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Disaggregation Of Revenue [Line Items]
Balance as of December 31, 2018	$ 2,363
Provision related to sales in the current year	1,076
Adjustments related prior period sales	(600)
Credit and payments made	(884)
Balance as of March 31, 2019	1,955
Trade Discounts, Allowances and Chargebacks [Member]
Disaggregation Of Revenue [Line Items]
Balance as of December 31, 2018	303
Provision related to sales in the current year	293
Credit and payments made	(316)
Balance as of March 31, 2019	279
Government Rebates and Other Incentives [Member]
Disaggregation Of Revenue [Line Items]
Balance as of December 31, 2018	1,880
Provision related to sales in the current year	729
Adjustments related prior period sales	(600)
Credit and payments made	(568)
Balance as of March 31, 2019	1,441
Returns [Member]
Disaggregation Of Revenue [Line Items]
Balance as of December 31, 2018	181
Provision related to sales in the current year	54
Balance as of March 31, 2019	$ 235

REVENUES (Details 2)

REVENUES (Details 2) - Sales Revenue, Net [Member] - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
AmerisourceBergen Specialty Group [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	60.00%	88.00%
McKesson Plasma and Biologics LLC [Member]
Entity Wide Revenue Major Customer [Line Items]
Concentration risk, percentage	17.00%

PROPERTY AND EQUIPMENT (Details

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Property and equipment
Property and equipment, gross	$ 456	$ 455
Less: accumulated depreciation	(317)	(303)
Total depreciable assets	139	152
Construction-in-progress	14
Property and equipment, net	153	152
Equipment [Member]
Property and equipment
Property and equipment, gross	306	306
Leasehold Improvements [Member]
Property and equipment
Property and equipment, gross	71	70
Furniture and Fixtures [Member]
Property and equipment
Property and equipment, gross	$ 79	$ 79

PROPERTY AND EQUIPMENT (Detai_2

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Property Plant And Equipment [Abstract]
Depreciation expense	$ 14,000	$ 13,000

INVESTMENTS (Details Narrative)

INVESTMENTS (Details Narrative) - USD ($) $ in Thousands	Jan. 01, 2018	Mar. 31, 2019	Mar. 31, 2018
Schedule Of Investments [Line Items]
Net realized (losses) gain on available-for-sales on marketable securities		$ (6,457)	$ 5,535
ASU 2016-01 [Member]
Schedule Of Investments [Line Items]
Cumulative effect adjustment on adoption of ASU 2016-01	$ 41,400	41,400
Cumulative effect on accumulated deficit, tax	$ 12,300	$ 12,300

INVESTMENTS (Details 1)

INVESTMENTS (Details 1) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Schedule Of Investments [Line Items]
Fair Value with Changes Recognized in Income	$ 43,124	$ 49,581
Measurement Alternative - No Readily Determinable Fair Value	527	538
Marketable Equity Securities [Member]
Schedule Of Investments [Line Items]
Fair Value with Changes Recognized in Income	43,124	49,581
Long-Term Investment At Cost [Member]
Schedule Of Investments [Line Items]
Measurement Alternative - No Readily Determinable Fair Value	$ 527	$ 538

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Accounts payable:
Clinical and regulatory expenses	$ 356	$ 83
Professional fee	1,961	2,157
Selling expenses	421	382
Manufacturing costs	1,756
Other vendors	692	980
Total accounts payable	5,186	3,602
Accrued interest payable, related parties	1,217	842
Accrued interest payable	2,306	2,138
Accrued expenses:
Payroll expenses	796	713
Accrued rebates	1,441	1,744
Other accrued expenses	122	83
Total accrued expenses	2,359	2,540
Total accounts payable and accrued expenses	$ 11,068	$ 9,122

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019USD ($)Number$ / shares	Dec. 31, 2018USD ($)Number
Principal Outstanding	$ 52,168	$ 55,172
Discount Amount	13,334	16,933
Carrying Amount	$ 38,834	$ 38,239
Shares Underlying Principal | Number	6,240	6,499
Notes payable, current	$ 7,000	$ 6,394
Notes payable, non-current	$ 1,922	1,021
Minimum [Member]
Conversion Price | $ / shares	$ 3.05
Maximum [Member]
Conversion Price | $ / shares	$ 10
2013 Notes payable [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 902	909
Carrying Amount	$ 902	909
2015 Notes payable [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 10	10
Carrying Amount	$ 10	10
2016 Notes payable [Member]
Term of Notes	Due on demand
Principal Outstanding	$ 843	843
Carrying Amount	$ 843	843
2016 Notes payable [Member] | Minimum [Member]
Interest rate	10.00%
2016 Notes payable [Member] | Maximum [Member]
Interest rate	11.00%
2017 Notes payable [Member]
Term of Notes	Due on demand
Principal Outstanding	$ 1,951	2,575
Carrying Amount	$ 1,951	2,575
2017 Notes payable [Member] | Minimum [Member]
Interest rate	5.00%
2017 Notes payable [Member] | Maximum [Member]
Interest rate	11.00%
2018 Notes payable [Member]
Principal Outstanding	$ 12,311	12,311
Discount Amount	7,847	9,233
Carrying Amount	$ 4,464	3,078
2018 Notes payable [Member] | Minimum [Member]
Interest rate	10.00%
Term of Notes	Due on demand
2018 Notes payable [Member] | Maximum [Member]
Interest rate	11.00%
Term of Notes	18 months
2019 Notes payable [Member]
Interest rate	11.00%
Principal Outstanding	$ 752
Carrying Amount	752
Notes Payable [Member]
Principal Outstanding	16,769	16,648
Discount Amount	7,847	9,233
Carrying Amount	8,922	7,415
Principal Outstanding, Current	14,569	12,449
Discount Amount Current	7,569	6,054
Notes payable, current	7,000	6,394
Principal Outstanding, Non Current	2,200	4,200
Discount Amount Non Current	278	3,179
Notes payable, non-current	$ 1,922	1,021
2016 Notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 270	270
Carrying Amount	$ 270	270
2017 Notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 27	39
Carrying Amount	$ 27	39
2018 Notes payable - related party [Member]
Interest rate	11.00%
Term of Notes	Due on demand
Principal Outstanding	$ 159	159
Carrying Amount	$ 159	159
2019 Notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Principal Outstanding	$ 14
Carrying Amount	14
Notes payable - related party [Member]
Principal Outstanding	470	468
Carrying Amount	470	468
Principal Outstanding, Current	470	468
Notes payable, current	$ 470	$ 468

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019USD ($)Number$ / shares	Dec. 31, 2018USD ($)Number
Principal Outstanding	$ 52,168	$ 55,172
Discount Amount	13,334	16,933
Carrying Amount	$ 38,834	$ 38,239
Shares Underlying Principal | Number	6,240	6,499
Convertible notes payable, Current	$ 15,157	$ 11,253
Convertible notes payable, Non Current	$ 389	5,485
Minimum [Member]
Conversion Price | $ / shares	$ 3.05
Maximum [Member]
Conversion Price | $ / shares	$ 10
2011 Convertible notes payable [Member]
Interest rate	10.00%
Term of Notes	5 years
Conversion Price | $ / shares	$ 3.05
Principal Outstanding	$ 300	300
Carrying Amount	$ 300	$ 300
Shares Underlying Principal | Number	98	98
2014 Convertible notes payable [Member]
Interest rate	10.00%
Principal Outstanding	$ 522	$ 519
Carrying Amount	$ 522	$ 519
Shares Underlying Principal | Number	186	184
2014 Convertible notes payable [Member] | Minimum [Member]
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.05
2014 Convertible notes payable [Member] | Maximum [Member]
Term of Notes	2 years
Conversion Price | $ / shares	$ 3.60
2016 Convertible Notes Payable [Member]
Interest rate	10.00%
Principal Outstanding	$ 62	$ 61
Carrying Amount	$ 62	$ 61
Shares Underlying Principal | Number	17	17
2016 Convertible Notes Payable [Member] | Minimum [Member]
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.60
2016 Convertible Notes Payable [Member] | Maximum [Member]
Term of Notes	2 years
Conversion Price | $ / shares	$ 4.50
2017 Convertible notes payable [Member]
Principal Outstanding	$ 1,895	$ 2,820
Discount Amount	108	349
Carrying Amount	$ 1,787	$ 2,471
Shares Underlying Principal | Number	618	899
2017 Convertible notes payable [Member] | Minimum [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.50
2017 Convertible notes payable [Member] | Maximum [Member]
Interest rate	13.50%
Term of Notes	3 years
Conversion Price | $ / shares	$ 10.31
2018 Convertible Notes Payable [Member]
Interest rate	10.00%
Principal Outstanding	$ 15,311	$ 19,556
Discount Amount	2,671	6,169
Carrying Amount	$ 12,640	$ 13,387
Shares Underlying Principal | Number	3,076	3,664
2018 Convertible Notes Payable [Member] | Minimum [Member]
Interest rate	6.00%
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.50
2018 Convertible Notes Payable [Member] | Maximum [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion Price | $ / shares	$ 10
2019 Convertible Notes Payable [Member]
Interest rate	10.00%
Principal Outstanding	$ 2,039
Discount Amount	1,804
Carrying Amount	$ 235
Shares Underlying Principal | Number	570
2019 Convertible Notes Payable [Member] | Minimum [Member]
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.50
2019 Convertible Notes Payable [Member] | Maximum [Member]
Term of Notes	1 year
Conversion Price | $ / shares	$ 4.50
Convertible Notes Payable [Member]
Principal Outstanding	$ 20,129	$ 23,256
Discount Amount	4,583	6,518
Carrying Amount	$ 15,546	$ 16,738
Shares Underlying Principal | Number	4,565	4,862
Principal Outstanding, Current	$ 19,421	$ 16,604
Principal Outstanding, Non Current	708	6,652
Discount Amount Current	4,264	5,351
Discount Amount Non Current	319	1,167
Convertible notes payable, Current	15,157	11,253
Convertible notes payable, Non Current	$ 389	$ 5,485
Shares Underlying Principal Current | Number	4,402	3,981
Shares Underlying Principal Non Current | Number	163	881
2012 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	Due on demand
Conversion Price | $ / shares	$ 3.30
Principal Outstanding	$ 200	$ 200
Carrying Amount	$ 200	$ 200
Shares Underlying Principal | Number	76	74
2015 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion Price | $ / shares	$ 4.50
Principal Outstanding	$ 200	$ 200
Carrying Amount	$ 200	$ 200
Shares Underlying Principal | Number	59	58
2017 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion Price | $ / shares	$ 10
Principal Outstanding	$ 5,000	$ 5,000
Discount Amount	218	311
Carrying Amount	$ 4,782	$ 4,689
Shares Underlying Principal | Number	545	533
2018 Convertible notes payable - related party [Member]
Interest rate	10.00%
Term of Notes	2 years
Conversion Price | $ / shares	$ 10
Principal Outstanding	$ 9,400	$ 9,400
Discount Amount	686	871
Carrying Amount	$ 8,714	$ 8,529
Shares Underlying Principal | Number	995	972
Convertible notes payable - related party [Member]
Principal Outstanding	$ 14,800	$ 14,800
Discount Amount	904	1,182
Carrying Amount	$ 13,896	$ 13,618
Shares Underlying Principal | Number	1,675	1,637
Principal Outstanding, Current	$ 14,800	$ 5,400
Principal Outstanding, Non Current		9,400
Discount Amount Current	904	311
Discount Amount Non Current		871
Convertible notes payable, Current	$ 13,896	5,089
Convertible notes payable, Non Current		$ 8,529
Shares Underlying Principal Current | Number	1,675	665
Shares Underlying Principal Non Current | Number		972

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Average stated interest rate	10.00%	10.00%
Average effective interest rate	48.00%	35.00%
Description of debt conversion	Certain notes with a $4.50 or a $10.00 stated conversion price in the second year of their two-year term are subject to automatic conversion into shares of Company common stock at a conversion price equal to 80% of the initial public offering price at the time of a qualified public offering.
Percentage of initial public offering price	80.00%
Aggregate outstanding convertible notes converted into common stock	$ 4,800,000
Percentage of outstanding convertible notes converted into common stock	14.00%
Warrants issued in conjunction with notes payable	$ 0
Warrants [Member]
Method of calculation of fair value of warrants		Binominal Monte-Carlo Cliquet Option Pricing Model
Minimum [Member]
Conversion Price	$ 3.05
Maximum [Member]
Conversion Price	$ 10

NOTES PAYABLE (Details 2)

NOTES PAYABLE (Details 2) $ in Thousands	Mar. 31, 2019USD ($)
Long Term Debt By Maturity [Abstract]
2019 (nine months)	$ 31,703
2020	20,465
Total	$ 52,168

NOTES PAYABLE (Details 3)

NOTES PAYABLE (Details 3)	Mar. 31, 2019$ / shares	Dec. 31, 2018$ / shares
Stock price	$ 10.30	$ 9.10
Term [Member]
Term	3 years 9 months	4 years
Risk-free Interest Rate [Member]
Warrants and rights outstanding, measurement input	2.22	2.48
Expected Volatility [Member]
Warrants and rights outstanding, measurement input	70	70
Warrants [Member] | Convertible Notes Payable [Member]
Stock price		$ 11.10
Warrants [Member] | Convertible Notes Payable [Member] | Exercise Price [Member]
Warrants and rights outstanding, measurement input		11.30
Warrants [Member] | Convertible Notes Payable [Member] | Term [Member]
Term		5 years
Warrants [Member] | Convertible Notes Payable [Member] | Risk-free Interest Rate [Member]
Warrants and rights outstanding, measurement input		3.05
Warrants [Member] | Convertible Notes Payable [Member] | Expected Volatility [Member]
Warrants and rights outstanding, measurement input		70

STOCKHOLDERS' DEFICIT (Details

STOCKHOLDERS' DEFICIT (Details Narrative) - USD ($)

Mar. 05, 2019

Dec. 29, 2017

Sep. 29, 2016

Sep. 12, 2016

Jun. 10, 2015

Jun. 10, 2014

Sep. 11, 2013

Oct. 31, 2018

Mar. 31, 2019

Mar. 31, 2018

Dec. 31, 2018

Sep. 11, 2014

Warrants outstanding

3,435,931

Warrants Issued with Notes (in shares)

1,220,000

Convertible notes prinicipal amount

$ 38,834,000

$ 38,239,000

Original Loan Principal Amount

44,169

Share-based compensation

$ 536,000

$ 710,000

Period remaining for recognition of unrecognized compensation cost

2 years 2 months 12 days

Common Stock [Member]

Issuance of common stock for exercise of warrants

81,332

2011 Stock Incentive Option Plan [Member]

Exercise price - options vested

$ 11.28

Total unrecognized compensation cost

$ 2,100,000

2011 Stock Incentive Option Plan [Member] | Stock Options [Member]

Share-based compensation

$ 500,000

$ 700,000

2011 Stock Incentive Option Plan [Member] | Share Based Compensation Award, Tranche One [Member]

Vesting percentage

33.33%

Vesting period

1 year

2011 Stock Incentive Option Plan [Member] | Share Based Compensation Award, Tranche Two [Member]

Vesting percentage

66.67%

Vesting period

2 years

Maximum [Member]

Conversion Rate (in dollars per share)

$ 10

Maximum [Member] | 2011 Stock Incentive Option Plan [Member] | Common Stock [Member]

Stock options granted to purchase common stock

357,000

Minimum [Member]

Conversion Rate (in dollars per share)

$ 3.05

GPB Debt Holdings II, LLC [Member]

Exercise price

$ 11.30

Warrants exercisable term

5 years

Date from which warrants are exercisable

Apr. 22, 2019

GPB Debt Holdings II, LLC [Member] | T.R. Winston & Company, LLC [Member]

Cash fee paid as percentage of gross proceeds from purchasers

5.00%

GPB Debt Holdings II, LLC [Member] | Securities Purchase Agreement [Member]

Principal amount of debentures and warrants issued

$ 12,200,000

GPB Debt Holdings II, LLC [Member] | Securities Amendment Agreement [Member]

Maturity date

May 1, 2019

Monthly redemption payment on principal amount

$ 1,000,000

GPB Debt Holdings II, LLC [Member] | Maximum [Member] | T.R. Winston & Company, LLC [Member]

Number of common stock to be purchased

120,000

GPB Debt Holdings II, LLC [Member] | Maximum [Member] | Securities Purchase Agreement [Member]

Number of common stock to be purchased

1,220,000

GPB Debt Holdings II, LLC [Member] | Maximum [Member] | Securities Amendment Agreement [Member]

Exercise price

$ 1.30

GPB Debt Holdings II, LLC [Member] | Minimum [Member] | Securities Amendment Agreement [Member]

Warrants to purchase shares of common stock

240,000

GPB Debt Holdings II, LLC [Member] | Senior Secured Convertible Promissory Note [Member]

Exercise price

$ 10.80

Warrants to purchase shares of common stock

240,674

Percentage of premium dilutive issuance price and number of shares issuable

10.00%

Warrants exercisable period after issuance

5 years

GPB Debt Holdings II, LLC [Member] | 10% Redeemable Debenture [Member]

Percentage of monthly payments interest rate

10.00%

Maturity date

Apr. 21, 2020

Monthly redemption payment on principal amount

$ 1,000,000

GPB Debt Holdings II, LLC [Member] | 10% Redeemable Debenture [Member] | Minimum [Member]

Debt instrument redemption amount

$ 20,000,000

GPB Debt Holdings II, LLC [Member] | Amended and Restated Debentures [Member] | Securities Amendment Agreement [Member]

Maturity date

Oct. 21, 2020

Monthly redemption payment on principal amount

$ 1,000,000

Monthly redemption payment, commencement date

Nov. 30, 2019

Conversion Rate (in dollars per share)

$ 10

GPB Debt Holdings II, LLC [Member] | Convertible Debt | Senior Secured Convertible Promissory Note [Member]

Convertible notes prinicipal amount

$ 13,000,000

Original Loan Principal Amount

$ 12,500,000

Original issue discount percentage

4.00%

KPM Tech Co., Ltd [Member] | Letter of Agreement [Member]

Common stock price

$ 15.32

Future capital increases

$ 13,000,000

Hanil Vacuum Co Ltd [Member] | Letter of Agreement [Member]

Common stock price

$ 3.68

Future capital increases

$ 1,000,000

Amended and Restated Warrants [Member] | GPB Debt Holdings II, LLC [Member] | Securities Amendment Agreement [Member]

Exercise price

$ 10

Exercise price, description

The exercise price of the amended and restated warrants also will be subject to reduction pursuant to a “full-ratchet” exercise-price antidilution adjustment in the event of a sale or issuance of common stock or common stock equivalents within 60 days following the merger at an effective price per share below the exercise price of the amended and restated warrants.

Amended and Restated Warrants [Member] | GPB Debt Holdings II, LLC [Member] | Maximum [Member] | Securities Amendment Agreement [Member]

Warrants to purchase shares of common stock

1,460,000

Private Placement [Member]

Units issued in offering

3,020,501

Unit price of offering

$ 2.50

Units issued in offering

$ 7,600,000

Warrants issued to broker of the offering

300,000

Exercise price

$ 3.50

$ 3.50

Warrants outstanding

2,225,036

Fair value of outstanding warrants

$ 1,800,000

$ 7,100,000

Number of warrants exercised

1,095,465

Proceeds from exercise of warrants

$ 3,800,000

Issuance of common stock for exercise of warrants

1,095,465

Adjustment to additional paid-in capital - warrants

$ 1,800,000

Private Placement [Member] | Letter of Agreement [Member]

Reduction in additional paid in capital

$ 720,000

Private Placement [Member] | KPM Tech Co., Ltd [Member] | Letter of Agreement [Member]

Purchase of common stock

$ 17,000,000

Common stock price

$ 4.50

Future capital investment

$ 13,000,000

Number of shares issued

3,777,778

Private Placement [Member] | Hanil Vacuum Co Ltd [Member] | Letter of Agreement [Member]

Purchase of common stock

3,000,000

Future capital investment

$ 1,000,000

Number of shares issued

666,667

Private Placement [Member] | KPM Tech Co., Ltd and Hanil Vacuum Co Ltd [Member] | Letter of Agreement [Member]

Purchase of common stock

$ 20,000,000

Private Placement [Member] | Replacement Warrants [Member]

Exercise price

$ 3.50

Warrants outstanding

1,095,465

Fair value of outstanding warrants

$ 2,500,000

Warrants Issued with Notes (in shares)

1,095,465

Warrant exercise inducement expense

$ 3,500,000

STOCKHOLDERS' DEFICIT (Details)

STOCKHOLDERS' DEFICIT (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Warrants outstanding, ending	3,435,931
Warrant [Member]
Warrants outstanding, beginning	3,436,431	5,265,432
Granted		1,542,000
Exercised	(500)	(2,385,317)
Cancelled, forfeited and expired		(985,684)
Warrants outstanding, ending	3,435,931	3,436,431

STOCKHOLDERS' DEFICIT (Detail_2

STOCKHOLDERS' DEFICIT (Details 1)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Number of Warrants Issued, Outstanding	3,435,931
Total, Exercisable	3,435,931
Warrants Issued in 2014 - Exercise Price $3.50 [Member]
Number of Warrants Issued, Outstanding	50,000
Weighted Average Remaining Contractual Life (Years), Outsanding	29 days
Weighted Average Exercise Price, Outsanding | $ / shares	$ 3.50
Total, Exercisable	50,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 3.50
Warrants Issued in 2014 [Member]
Number of Warrants Issued, Outstanding	50,000
Total, Exercisable	50,000
Warrants Issued in 2015 - Exercise Price $4.90 [Member]
Number of Warrants Issued, Outstanding	110,417
Weighted Average Remaining Contractual Life (Years), Outsanding	11 months 4 days
Weighted Average Exercise Price, Outsanding | $ / shares	$ 4.90
Total, Exercisable	110,417
Weighted Average Exercise Price, Exercisable | $ / shares	$ 4.90
Warrants Issued in 2015 [Member]
Number of Warrants Issued, Outstanding	110,417
Total, Exercisable	110,417
Warrants Issued in 2016 - Exercise Price $4.50 [Member]
Number of Warrants Issued, Outstanding	118,750
Weighted Average Remaining Contractual Life (Years), Outsanding	2 years 3 months
Weighted Average Exercise Price, Outsanding | $ / shares	$ 4.50
Total, Exercisable	118,750
Weighted Average Exercise Price, Exercisable | $ / shares	$ 4.50
Warrants Issued in 2016 - Exercise Price $4.70 [Member]
Number of Warrants Issued, Outstanding	75,000
Weighted Average Remaining Contractual Life (Years), Outsanding	2 years 1 month 2 days
Weighted Average Exercise Price, Outsanding | $ / shares	$ 4.70
Total, Exercisable	75,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 4.70
Warrants Issued in 2016 - Exercise Price $5.00 [Member]
Number of Warrants Issued, Outstanding	1,300,000
Weighted Average Remaining Contractual Life (Years), Outsanding	2 years 1 month 9 days
Weighted Average Exercise Price, Outsanding | $ / shares	$ 5
Total, Exercisable	1,300,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 5
Warrants Issued in 2016 [Member]
Number of Warrants Issued, Outstanding	1,493,750
Total, Exercisable	1,493,750
Warrants Issued in 2017 - Exercise Price $ 10.80 [Member]
Number of Warrants Issued, Outstanding	240,764
Weighted Average Remaining Contractual Life (Years), Outsanding	4 years 3 months
Weighted Average Exercise Price, Outsanding | $ / shares	$ 10.80
Total, Exercisable	240,764
Weighted Average Exercise Price, Exercisable | $ / shares	$ 10.80
Warrants Issued in 2017 [Member]
Number of Warrants Issued, Outstanding	240,764
Total, Exercisable	240,764
Warrants Issued in 2018 - Exercise Price $ 11.30 [Member]
Number of Warrants Issued, Outstanding	1,541,000
Weighted Average Remaining Contractual Life (Years), Outsanding	4 years 6 months 14 days
Weighted Average Exercise Price, Outsanding | $ / shares	$ 11.30
Total, Exercisable	1,541,000
Weighted Average Exercise Price, Exercisable | $ / shares	$ 11.30
Warrants Issued in 2018 [Member]
Number of Warrants Issued, Outstanding	1,541,000
Total, Exercisable	1,541,000

STOCKHOLDERS' DEFICIT (Detail_3

STOCKHOLDERS' DEFICIT (Details 2) - 2011 Stock Incentive Option Plan [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Options outstanding, beginning	6,642,200	6,775,200
Granted or deemed issued		357,000
Exercised	(200)	(170,000)
Cancelled, forfeited and expired		(320,000)
Options outstanding, end	6,642,000	6,642,200
Options exercisable	6,153,778	5,958,783
Options available for future grant	2,358,000	2,357,800
Options outstanding, beginning	$ 4.40	$ 4.12
Granted or deemed issued		11.28
Exercised	5	4.59
Cancelled, forfeited and expired		6.06
Options outstanding, end	4.40	4.40
Options exercisable	$ 4.01	$ 3.87

LEASES (Details Narrative)

LEASES (Details Narrative)	1 Months Ended	3 Months Ended
	Dec. 31, 2018USD ($)ft²	Mar. 31, 2019USD ($)ft²	Mar. 31, 2018USD ($)
Leases [Line Items]
Deferred rent | $		$ 201,000	$ 124,000
Weighted average remaining lease term		6 years 10 months 24 days
Weighted average discount rate		13.80%
Torrance, California [Member]
Leases [Line Items]
Operating lease, leased space | ft²		13,734
Operating lease, base rental per month | $		$ 48,087
Operating lease, additional space for rent | ft²	7,559	1,600
Operating lease, commencing date	Jun. 1, 2019
Operating lease, base rent per month for additional space | $	$ 27,590	$ 2,240
Operating lease base rent payable commencing date	Jan. 1, 2020
Operating lease, expiration date	May 31, 2026	Jan. 31, 2020
New York [Member]
Leases [Line Items]
Operating lease, additional space for rent | ft²		2,986
Operating lease, base rent per month for additional space | $		$ 5,500
Operating lease, expiration date		Dec. 30, 2019
Tokyo, Japan [Member]
Leases [Line Items]
Operating lease, leased space | ft²		1,322
Operating lease, expiration date		Sep. 30, 2020

LEASES (Details)

LEASES (Details) $ in Thousands	Mar. 31, 2019USD ($)
Leases [Abstract]
2019 (nine months)	$ 547
2020	980
2021	975
2022	1,003
2023 and thereafter	3,665
Total lease payments	7,170
Less: Interest	4,010
Operating lease liabilities	$ 3,160

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) ₩ / shares in Units, $ / shares in Units, $ in Millions	Oct. 31, 2018$ / shares	Sep. 29, 2017$ / sharesshares	Jul. 12, 2017USD ($)Numberkg$ / kg	Jun. 12, 2017USD ($)$ / sharesshares	Jun. 12, 2017KRW (₩)₩ / shares	Jul. 31, 2017USD ($)	Jul. 31, 2017KRW (₩)₩ / shares	Mar. 31, 2019$ / shares$ / kg	Mar. 31, 2019₩ / shares$ / kg	Dec. 31, 2018$ / shares	Dec. 31, 2018₩ / shares
Telcon, Inc. [Member]
Investment						$ 31.8	₩ 36,001,446,221
Investment, in per share | ₩ / shares							₩ 5,419
Investment, closing price | (per share)								$ 6.45	₩ 7,350	$ 7.43	₩ 8,280
Share repurchases, initial price per share | $ / shares	$ 7.60
Telcon, Inc. [Member] | Management Control Acquistion Agreement [Member]
Investment | $				$ 31.8
Telcon, Inc. [Member] | Management Control Acquistion Agreement [Member] | Korea (South), Won
Investment | ₩					₩ 36,000,000,000
Telcon, Inc. [Member] | API Supply Agreement [Member]
Investment, closing price | $ / shares				$ 4.79
Proceeds from supply agreement | $				$ 31.8
Telcon, Inc. [Member] | API Supply Agreement [Member] | Pharmaceutical Grade L-glutamine [Member]
Percentage of right to supply				25.00%	25.00%
Agreement term				15 years	15 years
Telcon, Inc. [Member] | API Supply Agreement [Member] | Korea (South), Won
Shares originally purchased (in shares) | shares				6,643,559
Investment, in per share | ₩ / shares					₩ 5,419
Proceeds from supply agreement | ₩					₩ 36,000,000,000
Telcon, Inc. [Member] | Raw Material Supply Agreement [Member]
Agreement term			5 years
Number of renewals | Number			10
Telcon, Inc. [Member] | Raw Material Supply Agreement [Member] | Pharmaceutical Grade L-glutamine [Member]
Weight of drug per supply agreement | kg			940,000
Unit price of grade L-glutamine | $ / kg			50					189	189
Purchase amount | $			$ 47
KPM Tech Co And Hanil Vacuum Co [Member] | Telcon, Inc. [Member]
Number of shares issued | shares		4,444,445
Common stock price | $ / shares		$ 6.60

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) $ / shares in Units, $ in Thousands		3 Months Ended		12 Months Ended
		Mar. 31, 2019USD ($)Number$ / shares		Dec. 31, 2018USD ($)Number$ / shares
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 38,834		$ 38,239
Shares Underlying Notes | Number		6,240		6,499
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[1]	10.00%	[2]
Date of Loan		Apr. 29, 2016	[1]	Apr. 29, 2016	[2]
Term of Loan		Due on Demand	[1]	Due on Demand	[2]
Principal Amount Outstanding		$ 20	[1]	$ 20	[2]
Highest Principal Outstanding		$ 20	[1]	$ 20	[2]
Hope Hospice [Member]
Short-term Debt [Line Items]
Interest Rate	[3]	10.00%		10.00%
Date of Loan	[3]	Jun. 3, 2016		Jun. 3, 2016
Term of Loan	[3]	Due on Demand		Due on Demand
Principal Amount Outstanding	[3]	$ 250		$ 250
Highest Principal Outstanding	[3]	$ 250		$ 250
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[1]	10.00%	[2]
Date of Loan		Feb. 9, 2017	[1]	Feb. 9, 2017	[2]
Term of Loan		Due on Demand	[1]	Due on Demand	[2]
Principal Amount Outstanding	[2]			$ 12
Highest Principal Outstanding		$ 12	[1]	$ 12	[2]
Yutaka Niihara [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[1],[4]	10.00%	[2],[5]
Date of Loan		Sep. 14, 2017	[1],[4]	Sep. 14, 2017	[2],[5]
Term of Loan		Due on Demand	[1],[4]	Due on Demand	[2],[5]
Principal Amount Outstanding		$ 27	[1],[4]	$ 27	[2],[5]
Highest Principal Outstanding		$ 904	[1],[4]	904	[2],[5]
Amount of Principal Repaid	[2],[5]			877
Amount of Interest Paid	[2],[5]			$ 95
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[1]	11.00%	[2]
Date of Loan		Feb. 10, 2018	[1]	Feb. 10, 2018	[2]
Term of Loan		Due on Demand	[1]	Due on Demand	[2]
Principal Amount Outstanding		$ 159	[1]	$ 159	[2]
Highest Principal Outstanding		$ 159	[1]	159	[2]
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate	[1]	10.00%
Date of Loan	[1]	Feb. 9, 2019
Term of Loan	[1]	Due on Demand
Principal Amount Outstanding	[1]	$ 14
Highest Principal Outstanding	[1]	14
Promissory Note Payable To Related Parties [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		470		468
Highest Principal Outstanding		$ 1,359		2,176
Amount of Principal Repaid				1,708
Amount of Interest Paid				$ 294
Yasushi Nagasaki [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[1]	10.00%	[2]
Date of Loan		Jun. 29, 2012	[1]	Jun. 29, 2012	[2]
Term of Loan		Due on Demand	[1]	Due on Demand	[2]
Principal Amount Outstanding		$ 200	[1]	$ 200	[2]
Highest Principal Outstanding		$ 200	[1]	$ 200	[2]
Conversion Rate (in dollars per share) | $ / shares		$ 3.30	[1]	$ 3.30	[2]
Shares Underlying Notes | Number		76,000	[1]	74,000	[2]
Yutaka & Soomi Niihara [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[1],[4]	10.00%	[2],[5]
Date of Loan		Nov. 16, 2015	[1],[4]	Nov. 16, 2015	[2],[5]
Term of Loan		2 years	[1],[4]	2 years	[2],[5]
Principal Amount Outstanding		$ 200	[1],[4]	$ 200	[2],[5]
Highest Principal Outstanding		$ 200	[1],[4]	$ 200	[2],[5]
Conversion Rate (in dollars per share) | $ / shares		$ 4.50	[1],[4]	$ 4.50	[2],[5]
Shares Underlying Notes | Number		59,000	[1],[4]	58,000	[2],[5]
Wei Peu Zen [Member]
Short-term Debt [Line Items]
Interest Rate		10.00%	[4]	10.00%	[5]
Date of Loan		Nov. 6, 2017	[4]	Nov. 6, 2017	[5]
Term of Loan		2 years	[4]	2 years	[5]
Principal Amount Outstanding		$ 5,000	[4]	$ 5,000	[5]
Highest Principal Outstanding		5,000	[4]	5,000	[5]
Amount of Interest Paid		$ 250	[4]	$ 250	[5]
Conversion Rate (in dollars per share) | $ / shares		$ 10	[4]	$ 10	[5]
Shares Underlying Notes | Number		545,000	[4]	533,000	[5]
Profit Preview International Group, Ltd. [Member]
Short-term Debt [Line Items]
Interest Rate	[6]	10.00%		10.00%
Date of Loan	[6]	Feb. 1, 2018		Feb. 1, 2018
Term of Loan	[6]	2 years		2 years
Principal Amount Outstanding	[6]	$ 4,037		$ 4,037
Highest Principal Outstanding	[6]	4,037		4,037
Amount of Interest Paid	[6]	$ 202		$ 202
Conversion Rate (in dollars per share) | $ / shares	[6]	$ 10		$ 10
Shares Underlying Notes | Number	[6]	430,000		420,000
Profit Preview International Group, Ltd. [Member]
Short-term Debt [Line Items]
Interest Rate	[6]	10.00%		10.00%
Date of Loan	[6]	Mar. 21, 2018		Mar. 21, 2018
Term of Loan	[6]	2 years		2 years
Principal Amount Outstanding	[6]	$ 5,363		$ 5,363
Highest Principal Outstanding	[6]	5,363		5,363
Amount of Interest Paid	[6]	$ 268		$ 268
Conversion Rate (in dollars per share) | $ / shares	[6]	$ 10		$ 10
Shares Underlying Notes | Number	[6]	565,000		552,000
Convertible notes payable - related party current [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 14,800		$ 5,400
Highest Principal Outstanding		$ 14,800		5,400
Amount of Interest Paid				$ 250
Shares Underlying Notes | Number		1,675,000		665,000
Promissory note payable and convertible notes payable - related party [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding		$ 15,270		$ 15,268
Highest Principal Outstanding		$ 16,159		16,976
Amount of Principal Repaid				1,708
Amount of Interest Paid				$ 1,014
Shares Underlying Notes | Number		1,675,000		1,637,000
Masaharu & Emiko Osato [Member]
Short-term Debt [Line Items]
Interest Rate	[5]			11.00%
Date of Loan	[5]			Dec. 29, 2015
Term of Loan	[5]			Due on Demand
Highest Principal Outstanding	[5]			$ 300
Amount of Principal Repaid	[5]			300
Amount of Interest Paid	[5]			$ 76
Lan T. Tran [Member]
Short-term Debt [Line Items]
Interest Rate	[2]			11.00%
Date of Loan	[2]			Feb. 10, 2016
Term of Loan	[2]			Due on Demand
Highest Principal Outstanding	[2]			$ 131
Amount of Principal Repaid	[2]			131
Amount of Interest Paid	[2]			$ 29
Masaharu & Emiko Osato [Member]
Short-term Debt [Line Items]
Interest Rate	[5]			11.00%
Date of Loan	[5]			Feb. 25, 2016
Term of Loan	[5]			Due on Demand
Highest Principal Outstanding	[5]			$ 400
Amount of Principal Repaid	[5]			400
Amount of Interest Paid	[5]			94
Convertible notes payable - related party non-current [Member]
Short-term Debt [Line Items]
Principal Amount Outstanding				9,400
Highest Principal Outstanding				9,400
Amount of Interest Paid				$ 470
Shares Underlying Notes | Number				972,000
[1]	Officer.
[2]	Officer
[3]	Dr. Niihara, a Director and Chief Executive Officer of the Company, is also the Chief Executive Officer of Hope Hospice.
[4]	Director.
[5]	Director
[6]	Mr. Zen, a Director of the Company, is the sole owner of Profit Preview International Group, Ltd.

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($) $ in Millions	May 13, 2019	Mar. 31, 2019
Subsequent Event [Line Items]
Aggregate outstanding convertible notes converted into common stock		$ 4.8
Percentage of outstanding convertible notes converted into common stock		14.00%
Scenario, Forecast [Member]
Subsequent Event [Line Items]
Aggregate outstanding convertible notes converted into common stock	$ 4.2
Percentage of outstanding convertible notes converted into common stock	12.00%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - USD ($)	Apr. 01, 2019	Mar. 31, 2019	Mar. 31, 2018
Common shares		$ 2,530,000	$ 275,000
Common Stock [Member]
Number of Shares Issued		307,500	25,000
Common Stock [Member] | Subsequent Event [Member]
Common shares	$ 711,550
Number of Shares Issued	103,590